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INTRODUCTION 
Growth is a fundamental biological activity that is characteristic of all living things. 
The term growth refers to either increase in cell size (hypertrophism) or increase in cell 
number (hyperplasticity). Both hypertrophism and hyperplasticity are essential for the 
growth, development, and viability of living organisms. The regulation of mammalian 
reproduction requires an elaborate coordination between regulation of the transient physi­
ological, biochemical, and morphological changes in the pregnant female, and the cellular 
proliferation, differentiation, migration, and organ formation in the embryo and fetus. 
Coordination of these events is achieved by complex networks of intercellular communica­
tors. Disruption of any of these communications would probably be deleterious to normal 
growth and development. 
Deranged human pregnancies leading to early deliveries of premature infants, who 
often survive but with permanent physical and mental impairments, are lifelong tragedies 
for the survivor, the family, and society. The magnitude of the human, social, and eco­
nomic predicaments caused by premature deliveries have been described to outweigh the 
predicaments caused by cancer, heart disease, and stroke combined (M. L. Casey et al. 
1985). Increased knowledge about the intercellular communicators that regulate mammal­
ian reproduction will provide the basis for better understanding of the processes involved 
in human reproduction and the causes for some birth defects. The improved understand­
ing will enable researchers to design procedures for the prevention and early diagnosis of 
some of these defects. 
The overall objective of Marit Nilsen-Hamilton's research group, of which I am a 
member, is to understand the regulation of the expression of genes responsible for the 
regulation of mammalian growth and development. This research is intended to add to 
the basic understanding of developmental events so that in the future more reproductive 
defects can be corrected. 
Biological Systems Employing Intercellular Communicators 
Immune system 
The most intensively studied biological system that employs intercellular communi­
cators is the immune system (Mohagheghpour et al. 1985, Macdonald and Nabholtz 1986, 
Dexter and Spooner 1987). The cells responsible for initiating the immune response are 
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T-lymphocytes, aided by accessory cells. Each lymphocyte carries a specific receptor on 
its surface. When lymphocytes encounter their specific antigen (presented by macro­
phages) they differentiate and proliferate to generate a clonal progeny with the same anti­
genic specificity. Activated helper T-lymphocytes secrete mediators called lymphokines 
(MacDonald and Nabholz 1986), which in turn activate other types of lymphocytes such as 
B-lymphocytes, cytotoxic T-lymphocytes, and suppressor T-lymphocytes to elicit and 
regulate the appropriate immune response (Arai et al. 1986, Mohagherghpour et al. 1985). 
Growth factors 
Polypeptide growth factors such as epidermal growth factor (EOF), transforming 
growth factor alpha (TGF-a), acidic fibroblast growth factor (aPGF), basic fibroblast 
growth factor (bFGF), platelet derived growth factor (PDGF), transforming growth factor 
beta (TGF-/9), insulin-like growth factors (IGFs), nerve growth factor (NGF), inter-
leukin-2 (IL-2), granulocyte macrophage colony stimulating factor (GM-CSF), growth 
hormone (GH), and prolactin (PRL), constitute a part of the intercellular communication 
system that regulates mammalian reproduction (Nilsen-Hamilton and Hamilton 1982, 
Adamson 1986, Gospodarowicz et al. 1986, 1987). TGF-a, bFGF, PDGF, TGF-/3, and 
IGFs appear to act during the early processes of mammalian development while the other 
growth factors act on specific, differentiated cell types during later stages of development 
(Nilsen-Hamilton 1988, CRC Reviews, in press). 
The participation of growth factors in developmental regulation is not restricted to 
mammalian species; for example, two separate homeotic loci in Drosophila meianogaster 
contain DNA sequences encoding growth factor-related sequences. EGF-Iike molecules 
are encoded by the locus called Notch (Wharton et al. 1985) and TGF-/9 gene sequences 
are found in the decapentapalegic locus (Padget et al. 1987). 
The regulation of cellular proliferation and animal development has been reviewed 
by several authors (Levi-Montalcini 1952, Cohen 1962, Holley 1975, Gospodarowicz and 
Moran 1976, Gospodarowicz et al. 1985, Deuel 1987, Nilsen-Hamilton 1988). 
Relationship between Growth Factors and Oncogenes 
Transformed cells often need fewer of the exogenous serum growth factors than are 
required by non-transformed cells for cellular proliferation (Temin et al. 1972, Vogel and 
Pollack 1974). The discovery that the amino acid sequence of the beta subunit of PDGF 
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is identical to the predicted amino acid sequence of the putative transforming protein 
P28^'^ of simian sarcoma virus (Waterfieid et al. 1983, Doolittle et al. 1983) laid the foun­
dation for understanding the significant relationship between oncogenes and growth rela­
ted genes. The list of oncogenes encoding growth related genes includes c-mt-2, v-erb B, 
v-fms, and the ras genes; these genes have homologues that encode for FGF, EGF recep­
tor (truncated), colony stimulating factor (CSF) receptor, and the GTP binding proteins 
respectively (Dickson and Peters 1987, Downward et al. 1984, Sherr et al. 1985, Mulcahy 
et al. 1985). The established link between oncogenes and cellular proliferation should 
yield a better understanding of the molecular mechanism of cellular transformation and 
carcinogenesis in humans. 
Role of Growth Factors in Regulating Cellular Function 
Growth factors are known to alter several cellular functions including: increasing the 
transport of nutrient across cell membranes (Holley and Kiernan 1974); changing the 
intracellular concentration of second messengers such as cyclic nucleotides in responsive 
cells (Otten et al. 1972, Seifert and Rudland 1974); altering the rate of protein synthesis 
(Hershko et al. 1971, Nilsen-Hamilton et al. 1980); and stimulating specific protein 
modifications, particularly the phosphorylation of proteins (Greengard 1978, Carpenter 
1979, Nilsen-Hamilton and Hamilton 1979, Berties et al. 1985) and the initiation of DNA 
synthesis (Cohen 1965, Carpenter and Cohen 1976). In addition to the general increase in 
protein synthesis, growth factors induce the production of specific secreted proteins from 
different mammalian cell lines (Nilsen-Hamilton et al. 1980, 1981, Nilsen-Hamilton and 
Hamilton 1982, Nilsen-Hamilton and Holley 1983, Hamilton et al. 1985). The pattern of 
secreted proteins from cells exposed to growth factors is cell type specific (Nilsen-Hamil­
ton and Hamilton 1983). Identification of the pattern of secreted proteins may prove 
useful in identifying the type of the original cell responsible for a particular tumor. 
Nilsen-Hamilton and co-workers are actively engaged in studying several secreted proteins 
whose production is regulated by growth factors. The list of proteins under intensive 
investigation at the present time includes cathepsin L, previously called major excreted 
protein (MEP) (Gottesman 1978); growth inhibitor induced protein (IIP48) (Nilsen-
Hamilton and Holley 1983, Thalacker and Nilsen-Hamilton 1987); superinducible proteins 
(SIPs) (Nilsen-Hamilton and Hamilton 1982); and mitogen regulated protein (MRP) 
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(Nilsen-Hamilton et al. 1980). MRP/PLF is the subject of this dissertation and it will be 
discussed in detail. 
History of MRP/PLF 
MRP/PLF is also known as proliferin (PLF). It was first identified as a family of 
glycoproteins with 30,000-38,000 dalton molecular weight, and it is released from growing 
mouse embryo fibroblast 3T3 cells into the medium upon stimulation with purified growth 
factor(s), particularly FGF and EGF (Nilsen-Hamilton et al. 1980). Later, a prolactin-like 
protein was identified from the nucleotide sequence of a cDNA clone derived from 
serum-stimulated murine Balb/C 3T3 cells, and the putative protein was named proliferin 
(PLF) (Linzer and Nathans 1983, 1984) because of its relation to prolactin and its associa­
tion with cellular proliferation (Linzer and Nathans 1984). The cDNA sequence of PLF 
contains a hydrophobic sequence similar to the signal sequence found in most secreted 
proteins, and it also contains four glycosylation consensus sequences (Asn-X-Ser/Thr), one 
of which is in the signal sequence. The amino acid sequence derived from the PLF 
cDNA has 32% amino acid sequence identity with mouse prolactin (mPRL) (Linzer and 
Nathans 1984, Parfett et al, 1985). Therefore it belongs to the prolactin-growth hormone 
(PRL-GH) family of hormones which also includes the placental lactogens (chorionic 
somatomammotropins) (PLs). It is now well established that PLF and MRP are identical 
(Denhardt et al. 1986, Parfett et al. 1985, Nilsen-Hamilton et al. 1987). 
MRP/PLF Tissue Distribution 
A survey of the occurrence of MRP/PLF mRNA in several mouse tissues including 
liver, kidney, ovary, pituitary gland, placenta, fetal brain, and whole fetus revealed the 
presence of the mRNA only in placental tissues (Linzer and Nathans 1985). The expres­
sion of the mRNA was detectable in 8-day old placenta, and reached a peak level at the 
tenth day of gestation (Linzer and Nathans 1985). MRP/PLF has recently been detected 
in the amniotic fluid of mice (Lee et al. 1988, this dissertation). 
Using immunofluorescence and avidin-biotin-peroxidase immunocytochemistry, 
Jang and Nilsen-Hamilton provided evidence for the presence of MRP/PLF in the 
trophoblasts and giant cells in the basal layer of mouse placental slices between days 9 and 
13 of gestation (Jang 1987, Nilsen-Hamilton et al. 1988). The proportion of cells contain­
ing MRP/PLF drops suddenly after the 13th day of gestation (Jang 1987). 
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Based on the following observations: 
(a) the stimulation of MRP/PLF production in mammalian cell cultures by 
growth factors (Nilsen-Hamilton et al. 1980), 
(b) the occurrence of MRP/PLF mRNA in mouse placental tissues (Linzer 
and Nathans 1985), 
(c) the occurrence of MRP/PLF in mouse placental tissues (Jang 1987, 
Nilsen-Hamilton et al. 1988, Lee et al. 1988), and 
(d) the 32% amino acid sequence homology between mouse MRP/PLF and 
mouse PRL (Linzer and Nathans 1984), 
I propose MRP/PLF as a new placental hormone with a probable regulatory role during 
mammalian embryogenesis and fetal development. 
Placenta 
The mammalian placenta may be defined as a transient organ formed by the fusion 
of maternal and fetal tissues inside the maternal uterus. The placenta is a highly vascu­
larized tissue with maternal and embryonic blood capillaries in close proximity that allows 
the exchange of materials between mother and fetus, while maintaining a barrier between 
the two bloodstreams. Besides allowing for the exchange of heat and materials, the 
placenta provides both the mother and fetus with necessary hormones and acts as an 
immunological barrier between the fetus and mother. The hormones produced by the 
placental tissues play a role in the maintenance of pregnancy and the production of a 
viable (Ogren and Talamantes 1988). The production of hormones by the placenta is cell 
type specific, i.e., progesterone is produced by the trophoblastic giant cells of rats and 
mice (Deane et al. 1962), and human placental lactogen (hPL) and human chorionic 
gonadotropin (hCG) have been localized to the villous syncytotrophoblastic layer of human 
placenta (Gaspard et al. 1980). MRP/PLF has been localized to the giant cells of the 
basal layer of CF-1 mouse placenta during the days 9-13 of gestation, but not to the 
labyrinth and the decidua (Jang 1987). 
If MRP/PLF has a significant physiological role during mammalian development, 
then one should expect to find MRP/PLF or MRP/PLF-like protein in placentae from 
species other than mouse. Recently a 34,000 dalton protein has been isolated from human 
placenta and found to be associated with cytotrophoblasts. The protein has a weak 
mitogenic activity when used to stimulate DNA synthesis in mouse embryo 3T3 cells (Sen-
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Majumdar et al. 1986). Its activity may be species and cell type specific or may be due to 
the presence of a contaminating mitogen in the preparation. Nilsen-Hamilton and co­
workers examined the ability of MRP/PLF antibodies to inhibit growth factor stimulated 
DNA synthesis in 3T3 cells. The results indicate a lack of mitogenic activity for 
MRP/PLF on 3T3 cells (Fienup 1985). 
Members of PRL Family of Proteins 
In addition to MRP/PLF the fetal component of the mouse placenta produces 
placental lactogens (PLs) that are members of the PRL-GH family of peptide hormones. 
Several PLs have been purified from different species and identified on the basis of their 
ability to mimic the lactogenic activity of pituitary PRL in various bioassays and radio­
receptor procedures (Talamantes 1975, Kelly et al. 1976, Forsyth 1986). The species from 
which PL(s) have been purified and characterized include human (Josimovich and 
Maclaren 1962, Hunt el al. 1981), rhesus monkey (Shome and Friesen 1971), rat (rPL-II, 
Robertson and Friesen 1975; rPL-I, Robertson et al. 1982), hamster (haPL-II, Southard et 
al. 1986, haPL-I, Southard et al. 1987), sheep (Hurley et al. 1975), cattle (Murthy et al. 
1982), baboon (Josimovich et al. 1973), goat (Becka et al. 1977), and mouse (mPL-II, 
Colosi et al. 1982; mPL-I, Colosi et al. 1987a). The complete amino acid sequence of four 
PLs are presently known; these PLs are mPL-I (Colosi et al. 1987b), mPL-II (Jackson et 
al. 1986), rPL-II (Duckworth et al. 1986), and hPL (Cooke et al. 1981). 
Structurally the PRL-GH family of peptides can be divided into two subfamilies, 
PRL-like peptides and GH-like peptides. Both share the presence of two intra-chain 
disulfide loops, a small loop at the carboxy terminal region, and a large loop comprising 
about 110 amino acid residues. PRL-like peptides contain an additional small disulfide 
loop at the amino terminal region of the peptide. The extra small loop allows for distinc­
tion between the two subfamilies. The structure-function relationship of these peptides is 
under intensive investigation (Nicoll et al, 1986, Chene et al. 1986). 
Placental lactogens share more common structural features with PRL than with GH 
(Hurley et al. 1977, Duckworth et al. 1986) except for hPL which is not only closer to GH 
structurally but the hPL gene is also part of the same gene cluster at chromosome 17 
(Barsh et al. 1983). 
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MRP/PLF Genome 
The genes for mPRL, mPL-I, mPL-II, mPLF, and mPRP have been mapped to 
mouse chromosome 13, whereas the mGH gene is mapped to chromosome 11 (Jackson-
Grusby et al, 1988). The mouse genome contains approximately four copies of PLF/MRP 
genes per haploid genome (Wilder and Linzer 1986). The two cDNA sequences that have 
been isolated differ in five nucleotides yielding protein sequences that differ in three 
amino acids in the putative mature protein sequences. These differences could not be at­
tributed solely to random errors of the reverse transcriptase used to produce the cDNA 
clones for two reasons: first, the error frequency for reverse transcriptase is known to be 
lower than what was observed (Maniatis et al, 1976), and second, all the mismatches occur 
at either serine or threonine residues. The significance of these two residues is not 
understood (Wilder and Linzer 1986). The occurrence of multiple gene copies is not 
unique for PLF/MRP among the PRL-GH family of peptides. The two hGH and the 
three hPL genes are clustered together at band q22-q24 on chromosome 17 (Barsh et al, 
1983). 
Regulation of MRP/PLF Production in 3T3 Cells 
The regulation of MRP/PLF production by growth factors from growing 3T3 cells 
probably occurs at the level of transcription (Nilsen-Hamilton et al. 1980, Linzer and 
Mordacq 1987, Parfett et al, 1985, Fienup et al. 1986). Pretreatment of growing 3T3 cells 
with cycloheximide (an inhibitor of protein synthesis in mammalian cells) inhibits the 
production of MRP/PLF (Nilsen-Hamilton et al, 1980) and its mRNA (Linzer and Mor­
dacq 1987) indicating the involvement of another intermediate protein in the regulatory 
mechanism of MRP/PLF production. The induction of MRP/PLF by growth factors is 
inhibited by actinomycin D (an inhibitor of RNA synthesis) (Nilsen-Hamilton et al. 1980). 
MRP/PLF may also be subject to posttranslational regulation by lysosomal prote­
olysis (Nilsen-Hamilton et al. 1981). Nilsen-Hamilton and her colleagues investigated the 
effects of ammonium chloride, ionophores (monensin and nigericin), and thiol-dependent 
protease inhibitors (leupeptin and antipain) on MRP/PLF production by growing Swiss 
3T3 cells. Their results revealed an increase in the rate of production of glycosylated 
MRP/PLF by the direct (thiol-dependent protease inhibitors) and the indirect (ammonium 
chloride, monensin, and nigericin) inhibition of lysosomal proteolysis, while the produc­
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tion rate of non-glycosylated MRP/PLF was not affected by the inhibition of lysosomal 
proteolysis (Nilsen-Hamilton et al. 1981, Nilsen-Hamilton et al. 1988). The results led 
Nilsen-Hamilton and coworkers to suggest MRP/PLF as either a secreted protein or a 
lysosomal protein with secretory regulation (Nilsen-Hamilton et al. 1988). 
Proteins targeted towards the lysosome generally carry mannose 6-phosphate 
residue(s) on their carbohydrate side chain allowing these proteins to bind to the mannose 
6-phosphate receptor located on the Golgi membranes. Recently, Lee and Nathans (1988) 
provided evidence for the specific binding of MRP/PLF to mannose 6-phosphate recep­
tors, on membranes isolated from fetal and maternal liver, and from placental tissue from 
pregnant mice. The protein used for this study was isolated from tissue culture medium 
conditioned by Chinese hamster ovary (CHO) cell-line carrying amplified copies of 
MRP/PLF complementary DNA in a mammalian expression vector. The identified recep­
tor was of the divalent-cation independent type (Lee and Nathans 1988) characterized 
previously (Sahagian et al. 1981). This finding is in agreement with Nilsen-Hamilton's 
previous observation that a portion of newly synthesized MRP/PLF is targeted towards 
the lysosome for degradation (Nilsen-Hamilton et al. 1981, Nilsen-Hamilton et al. 1988). 
The targeting of newly synthesized MRP/PLF to the lysosome for degradation is not 
unique for MRP/PLF; in fact, a close relative of MRP/PLF, i.e.y pituitary prolactin, is 
also subject to lysosomal degradation (Smith and Farquhar 1966, Farquhar 1971, Shenai 
and Wallis 1979). The process of degradation of newly synthesized secretory protein is 
known as crinophagy (De Duve 1969) 
In the case of pituitary PRL, secretion from the mammotropic cells is stimulated by 
thyrotropin releasing factor (TRF), which causes the secretory vesicle carrying PRL to 
fuse with the plasma membrane, leading to protein secretion. In the absence of TRF, the 
secretory vesicles fuse with the lysosomes, and the newly synthesized PRL is degraded 
rather than secreted (Smith and Farquhar 1966, Farquhar 1971). 
The production of MRP/PLF by placental cells could be regulated in a manner 
similar to that of prolactin in the pituitary. The secretion of MRP/PLF might be modu­
lated by a secretory stimulus that directs the transport of MRP/PLF containing vesicles to 
fuse with the plasma membrane for secretion as opposed to the intracellular lysosomes for 
degradation. 
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In vivo Regulation of MRP/PLF Production 
MRP/PLF produced by placental cells in mice is found in the amniotic fluid (Lee et 
al. 1988) and in the maternal serum (Jang et al. 1987, Lee et al. 1988) in addition to 
inside the placental cells themselves. 
One means of regulating the levels of MRP/PLF is by clearance via mannose 
6-phosphate receptors. To investigate the possible occurrence of mannose 6-phosphate on 
natural MRP/PLF found in the plasma and placentae of pregnant CF-1 mice, we started a 
collaboration with C. Gabel (Columbia Univ., New York) who is an authority on the 
mannose 6-phosphate receptor. The ability of MRP/PLF from CF-I mouse maternal 
plasma to bind to mannose 6-phosphate receptors is discussed in this dissertation.. 
Regulation of the expression of prolactin-like proteins in the mouse placenta is not 
the same for all proteins. mPL-I appears in maternal blood during the first half of 
gestation, reaches a peak level at mid-gestation, and declines thereafter, whereas mPL-II 
appears at mid-gestation and reaches a peak level later in gestation, and remains high 
until delivery (Soares et al. 1982). Proliferin-related protein (PRP) mRNA appears at 
mid-gestation and reaches a peak level two days later than MRP/PLF mRNA, which 
peaks at mid-gestation (Linzer and Nathans 1985). Although they appear at the same time 
in development, MRP/PLF and mPL-I are different proteins. The molecular weight of 
the PL-I polypeptide (29,000 daltons) is much larger than that of the deglycosylated 
MRP/PLF (21,000 daltons). Recently the mPL-I cDNA was sequenced; the sequence 
revealed a 32% sequence identity between mPL-I predicted amino acid sequence and 
mPLF and 36% with mPRP (Colosi et al. 1987b). 
Growth factors such as EGF selectively increase the levels of PRL mRNA in GH4 
cells (pituitary tumor cell line) by increasing the rate of PRL gene transcription (Murdoch 
et al. 1982). EGF also increases the level of MRP/PLF mRNA in 3T3 cells (Nilsen-
Hamilton et al. 1981, Nilsen-Hamilton et al. 1988). It is possible that EGF or TGF-a is 
responsible for the regulation of MRP/PLF production in vivo. 
The temporal regulation of MRP/PLF in mouse placenta coincides with that of 
TGF-a (Han et al. 1987, Wilcox and Derynck 1988). TGF-a is probably the embryonic 
form of EGF. EGF and TGF-a interact equipotently with human placental EGF recep­
tor. TGF-a is functionally equivalent to EGF (Massague 1983), and it has 32% amino 
acid sequence identity with EGF (Derynck et al. 1985, Hazarika et al. 1987). Both 
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MRP/PLF and TGF-a appear at high levels during mid-gestation, and are found in 
adjacent sites in the placenta, i.e., TGF-a mRNA has been found in the maternal decidua 
(Han et al. 1987), and MRP/PLF is localized in the giant cells of the basal zone adjacent 
to the maternal decidua. EOF regulates MRP/PLF production by 3T3 cells in culture 
(Nilsen-Hamilton et al. 1980). Thus, it is possible that TGF-a is responsible for the in 
vivo regulation of MRP/PLF production from the giant cells of the basal zone. TGF-a 
could also be the mitogen that stimulates the proliferation of placental cells (Nilsen-
Hamilton 1988). Thus, TGF-a could be the intercellular communicator responsible for 
the parallel increases in MRP/PLF production and placental weight (Jang 1987). 
The production of EGF by the salivary gland is regulated by testosterone (Byyny et 
al. 1974). Testosterone reaches a peak level at mid-gestation in mouse blood (Barkley et 
al. 1979, Soares and Talamantes 1983). The testosterone is believed to be synthesized by 
the placenta (Soares and Talamantes 1983, Matt et al. 1986). It is possible that the homol­
ogy between EGF and TGF-a extends beyond the protein coding sequence and includes 
the regulatory regions. Therefore TGF-a could also be regulated by testosterone. 
TGF-/8 reduces the level of secreted MRP/PLF (Chiang and Nilsen-Hamilton 1986) 
and MRP/PLF mRNA (Chiang 1986) in 3T3 cells in culture. TGF-fi has been detected in 
the placenta (Frolik et al. 1983), and therefore TGF-^ could be the modulator responsible 
for the rapid decline of MRP/PLF levels during the second half of mouse gestation. 
Based on the preceding observations we propose the following model for the regula­
tion of MRP/PLF production during mouse development: 
Testosterone produced by the placenta regulates the production of TGF-a by the 
maternal decidua, and TGF-a in turn regulates the production of MRP/PLF by the adja­
cent trophoblastic giant cells of the basal zone. The increased level of MRP/PLF is later 
reduced by the lysosomal degradation of MRP/PLF and/or the influence of TGF-/9 on the 
production of MRP/PLF by the trophoblastic giant cells. The results of experiments in 
which I examined the effect of antiandrogens on the levels of MRP/PLF in CF-1 mouse 
placenta and on the gestational profile of MRP/PLF in maternal plasma will provide a test 
for a part of the model describing the effect of testosterone on the production of 
MRP/PLF from the placental cells during pregnancy in CF-1 mice. 
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MATERIALS 
Equipment and Supplies 
Equipment used in this work included the following; Slab Gel Dryer Model 112SB 
(Bio-Rad, Richmond, CA), Kodak Diagnostic Film X-OMAT/AR (Fisher CDI/Photo-
graphic Division, Rochester, NY), Zeineh scanning densitometer (LK.B Instruments, 
Fullerton, CA), Gamma Trac 1191 gamma spectrometer (Tracor Analytic, Elk Grove 
Village, IL), Beta Trac liquid scintillation system (TM Analytic, Elk Grove Village, IL), 
Micro-Centrifuge Model 23SC (Allied/Fisher Scientific, Itasca, IL), Coat-A-Count total 
testosterone kit (Diagnostic Products Corp., Los Angeles, CA), Model TJ-6 tabletop 
centrifuge with model TJ-R refrigeration unit (Beckman Instruments, Palo Alto, CA), 
Bio-Gel P-6 desalting column (Bio-Rad, Richmond, CA), Caraway heparinized micro 
blood collecting tube (Fisher Scientific, Itasca, IL), Instant thin layer chromatography 
strips (Gelman, Ann Arbor, MI), and Hoefer Transphor Model TE5 (Hoefer Scientific 
Instruments, San Francisco, CA). 
Chemicals 
Flutamide was a gift from Schering Corp., Bloomfield, NJ. Cyproterone was a gift 
from Berlex Laboratories, Inc., Wayne, NJ. Mouse prolactin was a gift from Albert F. 
Parlow, Harbor-UCLA Medical Center, California. 
Other chemicals were purchased from commercial sources: Aldrich Chemical Co. 
(Milwaukee, WI), Amersham (Arlington Heights, IL), Bio-Rad Laboratories (Richmond, 
CA), Calbiochem-Behring (San Diego, CA), Collaborative Research (Bedford, MA), 
Eastman Kodak (Rochester, NY), Fisher Scientific (Pittsburgh, PA), ICN Chemicals and 
Radioisotopes (Irvine, CA), LKB (Gaithersburg, MD), Matheson, Coleman & Bell Chem­
icals, Ltd. (MCB) (Poole, England), Mobay Chemical Co. (New York, NY), Pharmacia 
(Piscataway, NJ), Pierce Chemical Co. (Rockford, IL), and Sigma Chemical Co. (St. Louis, 
MO). These chemicals and their sources are listed below: 
Acetone Fisher 
Acrylamide (recrystallized before use) Sigma 
Ammonium persulfate Bio-Rad 
Ampholine pH 5-8 LKB 
Benzamidine Sigma 
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Bovine serum albumin (BSA), crystallized 
Bromophenol blue 
Carbonic anhydrase 
Cytochrome c 
Dimethylsulfoxide (DMSO) 
2,S-Diphenyloxazole (PPO) 
Enzymobeads 
Epidermal growth factor (receptor grade) 
Epidermal growth factor antibody 
)9-Galactosidase 
Gelatin (porcine skin), type I, Bloom 300 
Glycerol 
Glycine 
Goat antibody to rabbit 7-globulin 
Haptoglobin 
P-Mercaptoethanol 
A^.A^'-Methylenebisacrylamide 
a-Methyl mannoside 
A^,^,A^',iV'-Tetramethylethylenediamine (TEMED) 
Ovalbumin 
Pansorbin {Staphylococcus aureus cells) 
Pharmalyte pH 3-10 
Phenylmethylsulfonylfluoride (PMSF) 
2-Propanol 
I25i_protein A 
Protein assay reagent 
Sephadex G-150 
Sodium dodecyl sulfate (SDS) 
'^^I-Sodium iodide 
Trasylol (Aprotonin) 
Trizma Base 
Trizma HCl 
Sigma 
Sigma 
Sigma 
Sigma 
Fisher 
Fisher 
Bio-Rad 
Collaborative Research 
Collaborative Research 
Sigma 
Sigma 
Sigma 
MCB 
Calbiochem-Behring 
Sigma 
Eastman Kodak 
Aldrich 
Calbiochem-Behring 
Sigma 
Sigma 
Calbiochem-Behring 
Pharmacia 
Sigma 
Fisher 
ICN 
Pierce 
Sigma 
MCB 
Amersham 
Mobay 
Sigma 
Sigma 
Other laboratory chemicals were obtained either from Sigma or Fisher. 
13 
METHODS 
Electrophoresis 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used for 
the analysis and the purification of MRP/PLF. The method is based on that described by 
Davis and by Ornstein (Davis 1964, Ornstein 1964) as modified by Nilsen-Hamilton et al. 
(1987). These modifications included the addition of 0.1% sodium dodecylsulfate (SDS) 
detergent to all the buffers, and the increase of the concentration of Tris buffer to 
600 mM in the resolving gel. The 1 mm thick resolving gel usually contained a linear 
acrylamide gradient of 7.5-15% (top to bottom). The stacking gel consisted of 5% acryl-
amide in 59 mM Tris-phosphate (pH 6.9) containing 0.1% SDS buffer. The stacking and 
the resolving gels were polymerized using 0.05% A^,JV,A^',N-tetramethylethylenediamine 
(TEMED) and ammonium persulfate (0.008% for the resolving gel and 0.1% for the 
stacking gel). The ratio of acrylamide to bisacrylamide was 37.5:1 in both stacking and 
resolving gel. The acrylamide was recrystallized from acetone before use. The electrode 
buffer consisted of 385 mM glycine, 50 mM Tris phosphate, and 0.1% SDS at pH 8.35. 
The same electrode buffer was used for both the anode and the electrode chambers. The 
electrophoresis was usually run for 6 to 7 hours at 12 mAmp per gel. A mixture of 
/9-galactosidase, BSA, ovalbumin, carbonic anhydrase, myoglobin, and cytochrome C in 
sample buffer was used for protein molecular weight standards. The resolved proteins 
were visualized by different methods, according to the quantity of the resolved protein 
and the type of radioactivity incorporated in the protein. Microgram quantities of protein 
were usually visualized by Coomassie blue R staining. The electrophoresed gel was im­
mersed in 0.05% Coomassie blue R in 25% 2-propanol, 10% acetic acid staining solution, 
and left gently shaking on a shaker for 2 hours. The stained gel was then transferred to 
destaining solution containing 10% 2-propanol and 10% acetic acid. Destaining was 
continued with two or three changes of destaining solution until a stain-free background 
was achieved. The destained gels were then placed on Whatman 3MM filter paper and 
dried under vacuum. The approximate weight(s) of the Coomassie blue stained bands 
(containing protein[s]) can be estimated by comparison with the stained bands of the 
molecular weight standards. 
Smaller quantities of proteins (10-100 ng) were visualized by silver staining accord­
ing to the method described by Morrissey (1981). The resolved gel was incubated in 50% 
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methanol, 10% acetic acid for 30 minutes, followed by a second incubation in 5% 
methanol, 7% acetic acid. The gel was then placed in 10% glutaraldehyde for 30 minutes, 
and rinsed thoroughly with.distilled water, either overnight or with several changes of 
water over a period of two hours. The washed gel was soaked in 5 MS/ml dithiothreitol 
(reducing agent) in water for 30 minutes. The reducing solution was poured off and the 
gel was placed in 0.1% silver nitrate solution for 30 minutes. The silver impregnated gel 
was rinsed with distilled water for 1 minute and soaked with agitation in the developer 
(3% sodium carbonate, 0.0185% formaldehyde) until the required level of staining was 
attained. The staining was stopped by making the developer 110 mM in citric acid 
(addition of 5.0 ml of 2.5 M citric acid solution to 100 ml developer) and agitating the gel 
for 10 minutes. The acidified developer was then poured off and the stained gel was 
washed several times with distilled water during 30 minutes. The gel was then soaked in 
0.03% sodium carbonate solution to prevent bleaching and a permanent record of the 
stained gel was made by photography. The gel was stored wet in heat-sealable food 
storage bags. The gel could also be dried on filter paper or a dialysis bag under vacuum 
and then mounted on a cardboard to keep it flat. 
Radiolabeled protein bands were visualized after exposing the gels to x-ray film 
using fluorography (Laskey and Mills 1976). The destained gel was soaked in two 
successive dimethylsulfoxide (DMSO) baths for 30 minutes each. Then the water-free gel 
was placed in a 2,5-diphenyloxazole (PPO)/DMSO bath for 3 hours, and then washed with 
distilled water to allow the precipitation of PPO in the gel. The PPO impregnated gel was 
placed on Whatman 3MM filter paper, and dried under vacuum. The dried, impregnated 
gel was exposed to preflashed x-ray film and kept at -70''C for a period of time (1-7 
days) that depended upon the amount of radioactivity in the protein bands. The exposed 
films were developed and scanned using a soft laser densitometer. The areas under the 
appropriate protein peaks were measured to estimate the quantity of protein in the band. 
Resolved gels containing '^^I-labeled protein were visualized after exposing the gels 
to x-ray film using autoradiography. The stained or unstained gels were placed on 
Whatman 3MM filter paper, dried under vacuum, exposed to preflashed x-ray film, and 
stored at -70°C for the required length of time. For more accurate estimates of the radio­
activity and hence the amounts of protein in the bands that appeared on either the fluoro-
gram or the autoradiogram, the protein bands corresponding to peaks on the dried gel 
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were cut out and the radioactivity measured using liquid scintillation spectrometry for 
beta-emitters or solid scintillation spectrometry for labeled proteins. 
Animals 
Outbred CF-1 mice obtained from Charles River Laboratories (Wilmington, MA) 
were used for the studies reported here. The animals were kept in a temperature-con-
trolled room (23-24''C), with a daily lighting schedule of 14 hours of light, 10 hours of 
darkness (lights on 0400-1800 h). Food and water were provided ad libitum. To induce 
natural mating, two males and four females were put in one cage during the dark period, 
the females were checked for plug formation before 0900 h the next morning, and the day 
of plug formation was designated day 0 of gestation. Blood samples (300 fil) were 
collected from female mice at different stages of gestation from the orbital sinus, using 
heparinized Caraway Micro blood collecting tubes (capacity 370 /il). The blood was 
centrifuged for 5 minutes in an Allied microcentrifuge Model 235C. The blood plasma 
was collected in 1.5 ml Eppendorff tubes and stored at -70^ until needed. 
Pregnant mice were killed at different stages of gestation by cervical dislocation. 
Several organs were quickly excised and placed in liquid nitrogen, then transferred to 
-70'C freezers until needed. The organs collected were brain, liver, mammary gland, 
uterus, ovaries, placenta, and embryos. 
Pregnant Sprague-Dawley rats were obtained from Holtzman Laboratory Animals 
(Madison, WI). The rats were kept in a temperature controlled room (23-24''C) with a 
daily lighting schedule of 12 hours of lights (lights on 0700-1900 h). They were provided 
with water and food ad libidum. Blood samples (0.4-0.5 ml) were collected from the tails 
of rats lightly anesthetized with ether, by cutting the tip of the tail and allowing the blood 
to flow into a 1.5 ml microcentrifuge tube, at different days of gestation. 
Tissue Extract Preparation 
The following procedure was used for most preparations. Approximately 100 mg of 
frozen placental tissue (or other tissue) was placed in a 12 x 75 mm glass tube and homo­
genized in 900 /il homogenization buffer (10 mM sodium phosphate, 150 mM sodium 
chloride, 0.2 mM magnesium sulfate, and 1.0 mM EDTA, pH 7.5) using a Tekmar Tissue-
mizer at 4"C. The homogenate was transferred to a 1.5 ml microcentrifuge tube and 
centrifuged at 13,000 x ^ for 10 minutes at 4°C. The supernatant was mixed with an 
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equal volume of homogenization buffer containing 19 mM EDTA to make the final 
concentration of EDTA equal to 10 mM in the extract. The prepared extract was stored 
at -70"C until needed. 
Tissue extracts used for mannose 6 phosphate receptor binding analysis contained 
200 mM /^-glycerol phosphate. 
Protein Determination 
Protein concentrations in tissue extracts were determined using the Coomassie blue 
G-250 Protein Assay Reagent from Pierce Chemical Co. according to the Micro-Assay 
Procedure of the manufacturers (Pierce Chemical Co.). This assay is based on the 
Bradford method (Bradford 1976) which involves the binding of Coomassie blue G-250 to 
protein. The protein-dye complex causes a shift in the absorption maximum of the dye 
from 465 to 595 nm. The procedure is sensitive to 1 /ig protein and the reaction is very 
rapid; it involves mixing 1.0 ml of properly diluted standard or sample with 1.0 ml of the 
Protein Assay Reagent and measuring the absorbances at 595 nm using deionized water to 
establish the baseline. Bovine serum albumin (BSA) was used as a standard. 
MRP/PLF and MRP/PLF Antibody 
MRP/PLF was prepared from concentrated serum-free Dulbecco Modified Eagle's 
(DME) Medium conditioned by growing 3T3 cells. The cells were grown in DME 
medium containing 10% calf serum (Irvine Scientific, Santa Ana, CA) until they reached 
half confluency, the medium was then replaced by fresh DME containing 1 /ig/ml FGF 
(partially purified preparation from bovine brain) and 10 ng/ml 12-0-tetradecanoyl 
phorbol 13-acetate (TPA), the cells were allowed to grow in this medium for 16 hours, 
then the medium was removed, the cells were washed three times with Tris Buffered 
Saline (TBS), and incubated in serum-free DME containing 10 ng/ml TPA and 10 mM 
ammonium chloride (to prevent lysosomal degradation of MRP/PLF) for 8 hours. The 
conditioned medium was collected, centrifuged for 30 minutes at 10,000 x g (Sorvall GSA 
rotor) and concentrated in an Amicon concentrator. The concentrated medium was again 
centrifuged for 30 minutes at 10,000 x g and then eluted through a Sephadex G-150 
column (140 cm long x 6.0 cm diameter) pre-equilibrated with 0.05 M ammonium 
bicarbonate. Fractions of 10 ml were collected, and their MRP/PLF content was 
monitored by SDS-PAGE as described before. The fractions containing MRP/PLF were 
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pooled, run through a pea-lectin Sepharose affinity column pre-equilibrated with 10 mM 
Tris/0.14 M sodium chloride pH 3.0 buffer. The protein was eluted with the same buffer 
containing 0.2 M a-methyl mannoside (or a-methyl glucoside). Fractions of 1 ml were 
collected and monitored for MRP/PLF by running SDS-PAGE followed by silver staining. 
The fractions containing MRP/PLF were pooled, concentrated, and dialyzed against 
10 mM Tris/S mM sodium chloride pH 8.0 buffer. The protein preparation was pure 
MRP/PLF except for a single band on the SDS-PAGE analysis corresponding to a 45,000 
dalton protein contaminant. Further purification of MRP/PLF was achieved by separating 
the protein on preparative SDS-PAGE gel, cutting the MRP/PLF band from the lightly 
stained (10 minutes staining) gel, and electroeluting the protein from the gel according to 
the method described by Hunkapiller et al. (1983). In this procedure the 7.5-15% gradient 
gel containing the separated MRP/PLF was stained for 20 minutes in 0.05% Coomassie 
blue, then destained in 5 mM Tris buffer pH 8.0. The band containing MRP/PLF was 
cut from the gel, diced into 1-mm square pieces, placed in a 5-cm petri dish, and 
incubated in elution buffer (0.05 M ammonium bicarbonate, 0.1% SDS) for 5 minutes at 
room temperature. The gel pieces were then carefully transferred into the gel loading 
well of the elution cell (previously tested for absence of leakage), covered with enough 
soaking buffer (0.4 M ammonium bicarbonate, 2% SDS, and 0.1% dithiothreitol) to fill the 
cross passage between the loading well and the sample collecting well of the elution cell. 
The cell was placed in the elution chamber. Enough elution buffer was added to allow 
for a closed electric circuit, and air bubbles were removed from beneath the elution cells. 
After 3-5 hours of soaking, the chamber was connected to a power supply with the 
cathode on the gel side, and subjected to 50 volts for 12-16 hours. The elution buffer 
was removed, replaced with dialysis buffer (0.01 M ammonium bicarbonate, 0.02% SDS) 
and the chamber was connected to the power supply adjusted to provide 80 volts for 24 
hours. The protein and Coomassie blue in the sample collection well of the elution cell 
were then carefully removed and placed in a microcentrifuge tube. The electroeluted 
protein was extracted from the protein-Coomassie blue mixture in dialysis buffer 
according to the procedure described by Wessel and Flugge (1984). In brief: one volume 
protein solution was mixed with four volumes of methanol in a 1.5 ml Eppendorff tube, 
vortexed, centrifuged in a microcentrifuge for 10 seconds, then one volume of chloroform 
was added, the mixture was vortexed, centrifuged for 10 seconds in a microcentrifuge, 
then three volumes of distilled water were added, the mixture was vortexed, centrifuged 
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for 1 minute in the microcentrifuge, then three volumes of distilled water were added, the 
mixture was vortexed, centrifuged for 1 minute in the microcentrifuge, the upper phase 
was carefully removed avoiding any disturbance to the protein at the chloroform-methanol 
interface. Then three volumes of methanol were added to the remainder, the mixture was 
vortexed and centrifuged for 2 minutes in the microcentrifuge, the supernatant was 
removed, and the resulting pellet was dried under nitrogen and stored at -ZO'C until 
needed for further use. 
Rabbit anti-MRP/PLF serum was obtained from Drs. Hamilton and Nilsen-Hamil-
ton, who raised it in a rabbit according to the method described by Nilsen-Hamilton et al. 
(1987). I used the batch designated 4296B for the radioimmunoassay. The antiserum does 
not react with prolactin (Nilsen-Hamilton et al. 1987) and it did not immunoprecipitate 
any protein other than MRP/PLF from media conditioned by 3T3 cells or other cells 
tested (mouse hepatocytes, human adenocarcinoma cells, mouse macrophage cell lines, 
human mammary carcinoma cells) or from cell lysates of 3T3 cells. It was found later 
that the antiserum reacts with a 45 kDa protein which is secreted by confluent 3T3 cells 
treated with ammonium chloride. The reactivity with this protein did not affect the 
radioimmunoassay because the MRP/PLF used for the standard and for preparing 
^^^I-MRP/PLF was free of the 45 kDa protein. 
Amino Acid Composition of MRP/PLF 
A sample of the purified (electroeluted) MRP/PLF was analyzed for amino acid 
composition. The analysis was done at the protein center at Iowa State University in 
Ames, Iowa. The amino acid composition was needed for two reasons: (1) to confirm the 
deduced amino acid composition from the sequenced cDNA for MRP/PLF (Linzer and 
Nathans 1984, Parfett et al. 1985), and (2) to provide a reasonable estimate of the concen­
tration of MRP/PLF in the stock solution of purified MRP/PLF that was to be used to 
make up MRP/PLF standards in the radioimmunoassay. 
The analysis was performed as follows: the sample (75 a»1 of MRP/PLF in 10 mM 
ammonium bicarbonate) was lyophilized under vacuum and hydrolyzed in hydrochloric 
acid vapor under vacuum for 1 hour at 150°C. The hydrolyzed protein sample was dis­
solved in deionized water and an aliquot equivalent to a tenth of the provided sample was 
placed on the sample slide of an Applied Biosystems 420A Derivatizer. The phenylthio-
carbamyl (PTC) derivative of amino acids was automatically transferred to the Applied 
19 
Biosystems 130A separation system in which the PTC-amino acids were separated on an 
HPLC system by reverse phase chromatography on a C]g-silica gel column and detected 
at 254 nm. 
Radloiodinatlon 
MRP/PLF was radioiodinated using Bio-Rad Enzymobead reagents. The Enzymo-
bead reagents consist of lactoperoxidase and glucose oxidase enzymes covalently attached 
to hydrophilic spheres. This method of radioiodination has advantages over other methods 
used for protein radioiodination. It is gentler on the protein and has fewer side reactions 
other than the halogenation of tyrosine side chains. Therefore the protein is more likely 
to retain biological activity (Morrison 1980). The solid phase format of the Enzymobead 
reagent provides an easy method for separating the enzymes from the reaction mixture by 
centrifugation. The radioiodination was carried out by mixing 1 fig purified MRP/PLF 
with 100 nCi fresh ^^^I-Na, SO /il Enzymobead reagent, and 25 /il 2% a-D-glucose for 25 
minutes at 24'C in a 1.5 ml Eppendorff tube. The a-D-glucose solution was usually 
prepared 1 day before it was used to allow for establishing the equilibrium between 
a-D-glucose and /9-D-glucose; the latter is the substrate for glucose oxidase on the 
Enzymobead reagent. At the end of 25 minutes incubation, the reaction mixture was 
microcentrifuged for 5 minutes and the supernatant was layered on top of a Bio-Gel P-6 
gel (Bio-Rad) column (5 cm long x 1.8 cm diameter) to separate the radiolabeled 
MRP/PLF from free ^^^I-Na. The column was pre-equilibrated with 50 mM sodium 
phosphate buffer pH 7.5 before loading the protein sample, and the protein was eluted 
with the washing buffer. Fractions of 1 ml were collected in 10 x 75 mm glass tubes 
containing 100 yX of 50 mM sodium phosphate and 1% crystalline BSA so that the final 
BSA concentration in the collected fractions was approximately 0.1%. The radioactivity in 
the fractions was measured in 5 (i\ aliquots from each fraction and the count per minute 
(cpm) plotted against the fraction number. This plot is shown in Fig. 1. The fraction 
corresponding to the void volume of the column contained the radiolabeled protein while 
the second peak contained the free '^^I-Na. The fractions of the first peak were pooled 
and run through a second column identical to the first column except that the 1 ml 
fractions were collected in tubes that did not contain BSA. The radioactivity in the 
fractions was measured (see Fig. 1). The fractions collected from the first and the second 
columns were monitored for acid insoluble radioactivity by the "instantaneous thin layer 
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Figure 1. Elution profile of radiolabeled MRP/PLF from Bio-gel P-6 columns. (The 
supernatant from the radioiodination reaction mixture was loaded on a Bio-
gel P-6 column, and the protein was eluted with 50 mM sodium phosphate 
buffer pH 7.5. Fractions of 1.0 ml were collected. The radioactivity in 
each fraction, measured on a 5 /ul aliquot, gave the profile indicated by the 
circles. Fractions 4, 5, and 6 were pooled and run through a second Bio-
gel P-6 column. Radioactivity in each fraction was measured as for the 
first column; the resulting elution profile is indicated by the squares) 
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chromatography" (ITLC) procedure described by Rosenberg and Teare (1977). Briefly, 
9 X 1 cm strips of silica impregnated glass fiber strips (ITLC/SG from Gelman Science 
Inc.) were marked at 1 -cm intervals leaving 2 cm from one end unmarked. Ten micro­
liters of 20% potassium iodide solution was spotted on the first marked centimeter, and 
allowed to dry. Then S ^1 of each fraction (one on each strip) was spotted on the 
potassium iodide spot, and allowed to dry. The samples were resolved by the ITLC 
procedure using a solution containing 2.5% acetic acid and 1.0 M hydrochloric acid. The 
strips were removed when the solvent front reached 1 cm from the top, air dried, cut 
according to the markings and the radioactivity on each interval was measured by the 
gamma spectrometer. The percentage of radioactivity remaining at the origin was 
considered incorporated into the protein. Usually 90% of the radioactivity in the pooled 
fractions that were used for radioimmunoassay were acid insoluble and remained at the 
origin, and only 2-5% of the applied radioactivity remained at the origin when late 
fractions were analyzed by the same procedure. The same method was used to radio-
iodinate receptor grade EOF. 
Two-dimensional Electrophoresis 
The iodinated, partially purified MRP/PLF preparation was resolved by the proced­
ure described by O'Farrell (1975) for the two-dimensional electrophoretic separation of 
proteins according to their isoelectric points and molecular sizes. This method was used to 
determine the feasibility of further purification of MRP/PLF by ion-exchange chroma­
tography. The first-dimension separation of proteins was according to differences in iso­
electric point (isoelectric focusing); it was carried out in tube gel unit (GT5 from Hoefer), 
and the unit was adapted to hold capillary tubes (14 cm x 1.2 mm internal diameter) by 
using available rubber septa. The gel mixture for the first dimension was prepared in a 
flask with side arm, as follows: 3.77% (w/v) acrylamide, 0.23% bisacrylamide, 9.2 M urea, 
2.0% (w/v) Nonidet P40 (NP-40), 1.6% (w/v) ampholine pH range 5-8, 0.4% (w/v) 
ampholine pH range 3-10, and 0.01% (w/v) ammonium persulfate were mixed by swirling 
and then degassed. Then 0.08% (v/v) TEMED was added, and the solution was immedi­
ately loaded into the gel capillary tubes (18 cm x 1.2 mM internal diameter) by capillary 
action until a height of 11.0 cm (previously marked) was reached, the bottom end of each 
filled tube was closed by clay. The gel mixture was overlayered with overlay solution 
containing 8.0 M urea and allowed to set for about 1 hour. Then the closed end of each 
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tube was etched with a glass knife and broken off, another etch was also made 4 cm from 
the other end of the tube and was also broken off leaving a 14 cm long capillary tube 
containing about 11.0 cm gel rod. The capillary tube gels were numbered, placed in the 
electrophoresis unit, and loaded with 10 (A sample overlay solution (9.0 M urea, 0.8% 
(w/v) ampholine pH range 5-8, and 0.2% ampholine pH range 3-10). The top reservoir 
was filled with degassed 0.02 M sodium hydroxide (cathode electrode solution) to just 
cover the capillary tubes. The lower reservoir was filled with degassed 0.01 M phosphoric 
acid (anode electrode solution) to a level of about 1 cm above the bottom of the tube. 
The gels were then pre-equilibrated by subjecting them to the following schedule of 
constant electric voltage: (1) 200 volts for IS minutes, (2) 300 volts for IS minutes, (3) 400 
volts for 30 minutes. The electric power then was disconnected, the upper reservoir was 
emptied and the remaining sodium hydroxide solution, and the sample overlay solution 
were gently removed from the surface of the gel. Sample or sample mixed with internal 
standard(s) (10/^1) then was carefully loaded into the appropriately marked tube gel, using 
a Hamilton syringe. The samples were overlaid with 10 nl sample overlay solution, and 
the top reservoir was refilled with cathode electrode solution. The gels were run at 400 
volts tor 22 hours. The resolved rod gels were gently and carefully extruded into troughs 
above the stacking gel which had been poured on top of a 7.5-15% gradient of resolving 
SDS polyacrylamide gels for the second dimension of separation according to the 
molecular size of the proteins. The stacking gels were made with special combs to hold 
the resolved rod gel and allow for one well on each side for protein molecular weight 
standards. Once the resolved gel and the protein standards are appropriately placed, the 
procedure is continued as described earlier for running SDS polyacrylamide gel electro­
phoresis. The separated proteins were visualized as described earlier. 
Immunoprecipitation of ^^^I-MRP/PLF 
To establish that the ^^^I-MRP/PLF retained its immunogenicity, the 
^^^I-MRP/PLF was immunoprecipitated with anti-MRP/PLF antiserum according to the 
method described by Chiang and Nilsen-Hamilton (1986). The procedure involves the 
incubation of '^^I-MRP/PLF with 1% normal rabbit serum and 7.6 /ig/ml killed Staphy­
lococcus aureus (pansorbin) in 100 fil immunoprecipitation buffer (150 mM sodium chlor­
ide, 10 mM sodium phosphate, 0.1% SDS, 1% Nonidet P-40, and 1% sodium deoxycholate 
at pH 7.2) for one hour at 4''C, followed by centrifugation at 3,000 rpm for 10 minutes at 
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4''C using a Beckman TJ-6 tabletop centrifuge. i-Cpm in both the supernatant and the 
pellet was measured in a gamma spectrometer. The supernatant was mixed with 1% 
anti-MRP/PLF (4269B), vortexed, and allowed to incubate for 1 hour at 4'C. The 
mixture was mixed with 10.3 fig/ml pansorbin for 1 hour at 4''C. The reaction mixture 
was then centrifuged at 3,000 rpm for 10 minutes at 4'C using the same Beckman tabletop 
centrifuge. The radioactivity (7-cpm) in both pellet (immunoprecipitate) and the 
supernatant were measured in the gamma spectrometer. The immunoprecipitate was 
washed three times with immunoprecipitation buffer. The final immunoprecipitate was 
resuspended in electrophoresis buffer to give a final concentration of 2.0% (w/v) SDS, 2% 
(v/v) )9-mercaptoethanol, 10% glycerol, 0.004% bromophenol blue, and 59 mM Tris-
phosphate (pH 6.9). The samples were resolved by gradient SDS polyacrylamide gel 
electrophoresis as described earlier in Methods. The '^^I-MRP/PLF band was visualized 
by autoradiography. For a direct estimate of the amount of immunoprecipitable 
^^^I-MRP/PLF, the band on the dried gel corresponding to ^^^I-MRP/PLF on the auto-
radiogram was cut out from the gel and its 7-cpm content was measured in the gamma 
spectrometer. 
Radioimmunoassays 
A radioimmunoassay was developed for determining the concentration of MRP/PLF 
in samples from different mouse blood plasma, serum and various mouse tissue extracts 
and conditioned media. 
MRP/PLF standards or samples and MRP/PLF antibody (obtained from Nilsen-
Hamilton) at a predetermined dilution (1:5,000) were incubated in 1.5 ml microcentrifuge 
tubes in buffer containing 10 mM sodium phosphate, 150 mM sodium chloride, 10 mM 
EOT A, and 1% crystalline BSA at pH 7.5 for a period of 6 hours at 4°C. At the end of 
the preincubation period '^^I-MRP/PLF (approximately 15,000 CPM/tube) was added, 
and the mixture was incubated for another 16 hours at 4°C. The total reaction volume 
was 250 jul containing 0.5 fil plasma at this stage. The separation of antigen-antibody 
complex from the free '^^I-MRP/PLF was achieved by incubating the mixture with 1% 
(w/v) pansorbin (Frohman et al. 1979, Ying 1981) for 1 hour at room temperature, 
followed by microcentrifugation for 10 minutes at room temperature. The supernatant was 
then carefully removed and the radioactivity of the pellet and the supernatant were 
measured in a GammaTrac 1191 radiospectrometer. The assay sensitivity, calculated as 
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the response which is two standard deviations away from the response for the zero dose, 
was 1.0 ng/ml (0.2 ng/tube) MRP/PLF. The radioactivity in the pellet from reactions 
containing 1000 ng/ml MRP/PLF was considered to be the nonspecific binding and it was 
subtracted from all the radioactivity of other pellets to obtain the specifically bound 
MRP/PLF in standards and test samples. The radioactivity in pellets from reactions 
containing no added MRP/PLF was considered to be the maximum binding. In this assay, 
44% of ^^^I-MRP/PLF was bound in the absence of added MRP/PLF, and 4% of 
MRP/PLF was found to bind when an excess of MRP/PLF was present in the reaction 
mixture (1000 ng/ml). When normal rabbit serum was used instead of anti-MRP/PLF 
antiserum at 1:5,000 dilution, 4.5% of '^^I-MRP/PLF was found to bind. The range of 
the assay is 1-100 ng/ml of MRP/PLF. 
The radioimmunoassay is specific for MRP/PLF (Fig. 2). Mouse prolactin at con­
centrations up to 1 /ig/ml does not react with anti-MRP/PLF serum. These concentra­
tions are much higher than the elevated concentrations of prolactin reached during the 
early days of pregnancy in C3H mice. The concentration of mouse prolactin reaches 
20-35 ng/ml in the maternal serum between day 5 and day 8 of pregnancy, and declines 
to below 5 ng/ml thereafter (Talamantes et al. 1984). We were unable to obtain mPL-I to 
examine its cross-reactivity with anti-MRP/PLF serum in this radioimmunoassay. The 
accuracy of the assay was evaluated by adding known quantities of MRP/PLF to plasma 
from a non-pregnant CF-1 mouse. When MRP/PLF was added to a final concentration of 
100 ng/ml, 80% of the MRP/PLF was detected. When it was added to a final concentra­
tion of 50 ng/ml, 88% of MRP/PLF was detected. 
The within-assay coefficient of variation in the assay was estimated by assaying a 
pooled sample of maternal plasma three times in duplicates in the same assay, and was 
calculated to be 2.2 ± 0.22 /ig/ml (mean ± SD) with 10% coefficient of variation; the same 
coefficient of variation was obtained when a plasma sample containing 5.6 m/taX 
MRP/PLF was assayed five times in duplicate. 
The between-assay coefficient of variation estimated by assaying the sample con­
taining 5.6 /ig/ml MRP/PLF in three different assays was calculated to be 13%. 
EGF in mouse submaxillary extract was determined by a similar radioimmunoassay 
except for the anti-EGF dilution, which was 1:10,000 instead of the 1:5,000 dilution used 
for MRP/PLF antiserum. 
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Figure 2. Radioimmunoassay specificity for MRP/PLF. (Various concentrations of either MRP/PLF or mouse 
prolactin were incubated with anti-MRP/PLF serum in the presence of a constant amount of 
^^^I-MRP/PLF, and B/BQ was determined as described in Methods. Each point represents the 
average of duplicate measurements. The open circles show the B/BQ in the presence of the indicated 
concentrations of MRP/PLF. The closed circles show B/BQ in the presence of various concentra­
tions of mouse prolactin) 
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Testosterone Radioimmunoassay 
Total testosterone in plasma collected from mice at different days of gestation, pla­
cental and other tissue extracts also collected at different days of gestation, was measured 
using a Coat-A-Count Total Testosterone kit from Diagnostic Products Corp. (Los 
Angeles) according to the manufacturer's instructions. 
The procedure is a solid phase immunoassay employing testosterone-specific anti­
body covalently bound to the wall of polypropylene tubes provided in the kit, which also 
contains six standards containing 0-30 ng/ml testosterone and buffered '^^I-testosterone 
solution (phosphate buffer, pH 8.0). The procedure was conducted as follows. Standard 
or sample (25 /il) was added to testosterone antibody-coated tubes, followed by 1.0 ml of 
buffered ^^^I-testosterone. The mixture was incubated 3 hours at 37°C, then the mixture 
was decanted thoroughly from the tubes. The bound radioactivity was measured in a 
gamma spectrometer. The specifically bound radioactivity was calculated by subtracting 
nonspecifically bound radioactivity from the bound radioactivity. Nonspecific binding 
was estimated by incubating 25 fil of the zero standard with 1.0 ml ^^^I-testosterone in 
plain (uncoated) 12 x 75 mm polypropylene tubes. The radioactivity specifically bound to 
the coated tubes containing zero testosterone standard was considered to be the maximum 
binding. The data were analyzed by the Logit-log representation provided with the kit. 
The sensitivity of the assay was reported to be 110 pg/ml by the manufacturer of the kit. 
Effects of Antiandrogens on the Concentration of EGF 
in Submaxillary Gland and MRP/PLF in Plasma and Placenta during Pregnancy 
Seven-week-old pregnant CF-1 mice were randomly divided into four groups with 
at least two mice per group. Starting at day 8 of gestation, blood was withdrawn from 
each mouse daily until day 15 of gestation (termination of treatment). Group 1 received 
no treatment (control). Group 2 mice received daily injections of 100 fil of a solution 
containing 1% gelatin in 150 mM sodium chloride (control). Group 3 received daily 
injections of 100 /il of a solution containing 3.0 mg (0.12 mg per gram body weight) 
flutamide in 1% gelatin and 150 mM sodium chloride. Group 4 received daily injections 
of 100 /il of a solution containing 3.0 mg (0.12 mg per gram body weight) cyproterone in 
1% gelatin and 150 mM sodium chloride. All injections were administered daily from day 
6 of gestation until the treatment was terminated. The injections were given in alternate 
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thigh muscles on consecutive days. The mice were killed on day IS of gestation by 
cervical dislocation, and the submaxillary glands and placenta from each mouse were 
collected, weighed, and stored at -IQ'C until needed. 
Protein "Western" Blotting 
Proteins resolved on SDS polyacrylamide gels by electrophoresis were transferred to 
nitrocellulose membranes employing the Hoefer Transfor Model TESO according to the 
procedure of Towbin et al. (1979). MRP/PLF was detected by the use of anti-MRP/PLF 
and radioiodinated Protein A according to the procedure described by Burnette (1981). 
Protein "Western" blotting was used to determine that MRP/PLF detected in plasma 
obtained from pregnant CF-1 mice was identical in size with the purified MRP/PLF used 
for RIA standard. The procedure involves resolving the standard MRP/PLF, plasma pro­
tein by SDS polyacrylamide gel electrophoresis as described earlier in Methods. The re­
solved gel was soaked in degassed transfer buffer (20 mM Tris, 192 mM glycine, and 20% 
[v/v] methanol, pH 8.3) for IS minutes at room temperature. The soaked gel was placed 
in a sandwich, made in the cassette (provided with the Transfor apparatus), and placed 
under transfer buffer in a large glass tray. The sandwich consisted of the following suc­
cessive layers: (1) a Dacron sponge on the first half of the cassette, (2) two sheets of 
Whatman 3MM filter paper, (3) a nitrocellulose membrane cut to the size of the gel and 
prewetted with transfer buffer, (4) the resolved gel soaked in transfer buffer, (S) two 
additional sheets of filter paper, and (6) the second half of the cassette. The two halves 
of the cassette were closed, pressed together to ensure the absence of air bubbles between 
the layers of the sandwich, and secured with rubber bands. The assembled cassette was 
then placed in the transfer chamber containing about 4.0 liters of transfer buffer. The 
transfer container was fitted with a heat exchanger coil to prevent any rise in temperature 
during the run. The buffer was mixed gently with a magnetic stirrer. The electrodes 
were connected in a way to allow the transfer of proteins towards the anode from the gel 
to the nitrocellulose membrane. The voltage was adjusted to 100 volts at the beginning of 
the run, and adjusted to maintain the current below 0.9 ampere by lowering the voltage 
whenever the current rose above 0.9 ampere. The electrotransfer was continued for 2 
hours and then the electric power was disconnected, the cassette was removed and dis­
assembled, and the gel was stained with Coomassie blue as described earlier in Methods. 
The nitrocellulose membrane was incubated for 30 minutes at 40''C with gentle agitation 
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in a solution containing 10 mM Tris-HCl, 0.9% sodium chloride pH 7.4 (Tris saline), 1% 
nonfat dry milk, and 1% BSA (blocking solution). The membrane was transferred to a 
fresh blocking solution containing anti-MRP/PLF diluted 1:100, and allowed to incubate 
with gentle agitation for 1.5 hours at room temperature. The nitrocellulose membrane was 
then rinsed with gentle agitation in Tris-saline without BSA for 20 minutes, and then 
washed twice with Tris-saline containing 0.05% NP40. After a final wash for 10 minutes 
with Tris-saline alone, the nitrocellulose membrane was incubated with gentle agitation in 
blocking solution containing 5 x 10^ cpm of ^^^I^Protein A for 30 minutes at room tem­
perature. The nitrocellulose membrane was washed again as described above, blotted with 
paper towels, wrapped in Saran wrap, and exposed at -70'C to preflashed Kodak X-ray 
film for 24 hours. The exposed film was developed and the bands appearing on the 
X-ray film were visually compared for molecular weight identity (Fig. 3). 
MRP/PLF Affinity for the Mannose 6-Phosphate Receptor 
To investigate the affinity of MRP/PLF in CF-1 mouse maternal blood, amniotic 
fluid, and in placental extract for the mannose 6-phosphate receptor, we collaborated with 
Dr. C. Gabel, to whom we sent lyophilized samples of maternal plasma representing three 
stages of pregnancy (days 5, 10, and 13), and one sample each of amniotic fluid and 
placental extract, both from the same mouse at day 13 of pregnancy. A duplicate of each 
of the samples was kept in our laboratory for determining the concentration of MRP/PLF. 
In Dr. Gabel's laboratory the samples were subjected to the following treatment: 
(a) Samples were reconstituted with distilled water. 
(b) An aliquot was mixed with ^^h-ligand (standard for mannose 6-phosphate 
receptor binding). 
(c) The aliquot containing ^^h-ligand was applied to a mannose 6-phosphate 
receptor affinity column prepared according to the method described by Varki and 
Kornfeld (1983). 
(d) The column was then washed with 15.0 ml column buffer (50 mM sodium 
phosphate, 150 mM sodium chloride, 5.0 mM /9-glycerol phosphate, 2.0 mM EDTA, and 
0.1 mM PMSF). Fifteen 1.0 ml fractions were collected and the bound molecules were 
eluted with 15 ml column buffer containing mannose 6-phosphate. Fifteen 1.0 ml 
fractions were collected. An aliquot from each fraction was assayed for ^^h-ligand 
content to establish the run through fractions (fractions containing no binding activity for 
Figure 3. Autoradiogram of protein "Western" blot of 10-day maternal plasma probed 
with nonimmune serum (A) or anti-MRP/PLF serum (B) and detected by 
radioiodinated Protein A 
A B 
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the mannose 6-phosphate receptor) and the bound fractions (fractions containing 
molecules that bind to mannose 6-phosphate receptors). Fractions 4-9 were usually the 
run through fractions and fractions 20-25 were the bound fractions. 
(e) The run-through fractions and the bound fractions were pooled separately, 
lyophilized, and sent back to our laboratory for the determination of MRP/PLF content in 
each of the two fractions by the radioimmunoassay. 
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RESULTS 
MRP/PLF Purification 
The procedure employed for MRP/PLF purification from serum free medium con­
ditioned by stimulated and growing 3T3 cells (described in Methods) yielded a preparation 
that contained MRP/PLF and a 45 KDa protein. Fig. 4 shows the autoradiogram of the 
SDS PAGE resolved radiodinated MRP/PLF from the partially purified MRP/PLF which 
shows the presence of two bands corresponding to MRP/PLF and to the 45 kDa protein. 
The 45 kDa protein accounted for approximately 20% of the protein content in the 
preparation. 
MRP/PLF was further purified by separation on a preparative SDS PAGE gel 
(described in Methods). The protein band corresponding to MRP/PLF and the band 
corresponding to the 45 KDa protein were cut from the gel. The proteins were separately 
electroeluted from the diced gel and dialyzed against 10 mM sodium bicarbonate solution 
as described in Methods. They were then extracted from the solution containing Coo-
massie blue and SDS, lyophilized, and resuspended in 10 mM ammonium bicarbonate. 
Fig. 5 is a photograph of an autoradiogram of radioiodinated purified MRP/PLF resolved 
by SDS polyacrylamide gel electrophoresis. To estimate the concentration of MRP/PLF, 
the purified protein and ovalbumin standards were resolved by SDS polyacrylamide gel 
electrophoresis, silver stained, and scanned using a densitometer. The corresponding areas 
under the protein peaks in the tracing were determined. The ovalbumin standard peaks 
were used to establish a standard curve, shown in Fig. 6, relating the areas under the 
peaks to the known concentration of ovalbumin. The concentration of MRP/PLF was 
estimated to be 43 ng/ml by comparing the area under the MRP/PLF peak to the 
ovalbumin standard curve. 
MRP/PLF Amino Acid Composition 
The amino acid composition of purified MRP/PLF was determined by using the 
Applied Biosystems Amino Acid Analyzer at the Protein Facility at Iowa State University. 
Table 1 shows the concentration of each amino acid detected in the preparation by the 
amino acid analyzer and as predicted from the cDNA sequence of MRP/PLF. The con­
centration of MRP/PLF was estimated from the concentration of four amino acids (argi-
nine, glutamic acid, threonine, and tyrosine) which gave an expected/observed concentra-
Figure 4. Autoradiogram of SDS polyacrylamide gel containing radioiodinated, parti­
ally purified MRP/PLF. (The presence of a 45 kDa protein contaminant 
and MRP/PLF are indicated. Lane A contains ^^S-methionine labeled 
standards, lane B contains radioiodinated MRP/PLF without mercaptoeth­
anol, and lane C contains radioiodinated MRP/PLF with mercaptoethanol) 
45K 
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Figure 5, Autoradiogram of SDS poiyacryiamide gel containing radioiodinated puri­
fied MRP/PLF. (The arrow indicates the position of '^^I-MRP/PLF. The 
numbers on the left are the molecular weights of protein standards run on 
the same gel) 
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Figure 6. Calibration curve of ovalbumin concentrations obtained from densitometric 
scans of ovalbumin standards. (The integrated scan area in lanes E through 
I of Fig. 2 was plotted as a function of ovalbumin concentration. The con­
centration of MRP/PLF in the final preparation was obtained by densitom­
etry and the use of this standard curve) 
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Table 1. Amino acid composition of MRP/PLF® 
Amino Residues per Percent 
acid molecule^ of total 
expected 
Alanine 11 5.41 
Arginine 7 3.45 
Asparagine*^ 15 7.39 
Aspartic acid" 14 6.90 
Cysteine^ 16 2.96 
Glutamine^ 3 1.48 
Glutamic acid" 13 6.4 
Glycine® 7 3.45 
Histidine 4 1.97 
Isoleucine^ 15 7.39 
Leucine 26 12.81 
Lysine 15 7.39 
Methionine^ 9 4.43 
Phenylalanine 9 4.13 
Proline 6 2.96 
Serine^ 19 9.36 
Threonine*^ 9 4.43 
Tryptophan^ 2 0.99 
Tyrosine 5 2.46 
Valine^ 8 3.94 
Percent % Observed/ Amino acids 
of total % Expected analyzed® 
observed 
7.22 1.22 116.8 
3.43 0.91 57.3 
8.48 0.54 132.1 
8.25 0.96 128.2 
9.51 2.54 150.2 
1.86 0.86 30.9 
6.5 0.8 109.3 
12.09 0.86 201.9 
9.2 1.14 142.5 
0.78 0.16 
5.84 1.2 91.8 
4.58 1.42 75.2 
8.00 0.78 131.2 
5.12 1.05 85.5 
2.89 1.08 46.8 
6.8 1.58 113.1 
®The amino acid composition was analyzed on 7.5 y\ of the sample. The analysis 
provided the number of pmoles of each amino acid residue. MRP/PLF concentration was 
calculated from the amino acids that are not affected by acid hydrolysis. The number of 
moles of protein was obtained by dividing the number of moles of amino acids by the 
number of residues of the corresponding amino acid per molecule of protein. 
^Expected residues per molecule, based on cDNA sequence (Linzer and Nathans 
1984, Parfett et al, 1985). 
'^Expressed in pmoles. 
•^These amino acids are affected by acid hydrolysis. 
^Glycine was present in the gel from which MRP/PLF was isolated, and therefore 
did not enter into the calculation of MRP/PLF concentration. 
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tion ratios of about one. The estimated concentration of MRP/PLF was 43 /ig/ml which 
compares well with the MRP/PLF concentration estimate from silver staining analysis, 
I.e., 43 /ig/ml. 
Characteristics of MRP/PLF 
MRP/PLF was prepared by using the lactoperoxidase Enzymobead method de­
scribed in Methods. The radioiodinated MRP/PLF was separated from the free Na'^^I on 
a Bio-Gel P-6 desalting column. The acid precipitable radioactivity (^^^I-MRP/PLF in 
the 1.0 ml fractions from the column was monitored by using ascending thin layer 
chromatography as described in Methods. The acid precipitable radioactivity in fractions 
4-6 (void volume containing ^^^I-MRP/PLF) was estimated to be 50.-70%. Fractions 4-6 
were pooled and run through a second desalting column which yielded fractions (4-6) 
containing over 75% acid precipitable radioactivity. Usually '^^I-MRP/PLF samples con­
taining less than 75% acid precipitable radioactivity were run through another Bio-Gel 
P-6 column. The specific activity of the ^^^I-MRP/PLF prepared by this procedure 
varied considerably from preparation to preparation and ranged from 2 ftCi/ng to 
98 nCi/ng, 
Development of MRP/PLF Radioimmunoassay 
A radioimmunoassay was developed for estimating the concentration of MRP/PLF 
in samples from various sources such as plasma, conditioned tissue culture media, and 
tissue extracts. The assay was developed by using the purified MRP/PLF, polyclonal 
anti-MRP/PLF antibody, and killed Staphylococcus aureus (pansorbin) to precipitate the 
antigen-antibody complex. The assay was optimized for buffer, concentration of anti-
MRP/PLF, and for precipitating the immunocomplex. 
Concentration of Anti-MRP/PLF 
The optimum concentration of anti-MRP/PLF was determined by varying the con­
centration of anti-MRP/PLF in the presence of a constant amount of '^^I-MRP/PLF and 
in the absence of nonlabeled MRP/PLF (Fig. 7). The concentration of anti-MRP/PLF 
(1:5,000 dilution) at which 40-50% (Aubert 1977, Felber 1974) of ^^^I-MRP/PLF was 
complexed with anti-MRP/PLF was chosen for the radioimmunoassay. The complex pre­
cipitated with pansorbin. 
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Figure 7. Anti-MRP/PLF titration curve. (Different concentrations of anti-
MRP/PLF were incubated with radioiodinated MRP/PLF (15,000 cpm per 
reaction tube) in radioimmunoassay buffer (250 /il final volume) for 14 h 
at 4°C. The bound ^^^I-MRP/PLF was precipitated by the addition of 
immobilized protein A (Pansorbin). 7-Cpm in the precipitate was 
measured) 
41 
Separation of Free from Antibody Bound MRP/PLF 
Two procedures for the separation of the free from the antibody bound antigen 
were compared. These were (a) the double antibody procedure in which the antigen-anti­
body complex was precipitated with goat antibody to rabbit 7-globulin (second antibody) 
from Calbiochem, and (b) the use of pansorbin as an immunocomplex precipitating agent. 
The two precipitating agents gave similar results. 
Pansorbin was chosen as the reagent for separating the antigen-antibody complex 
from the free antigen because (1) it requires a shorter period of incubation due to its very 
high affinity of the protein A on pansorbin for the antigen-antibody complex (2 x 10^ 
M~^) (Ying 1981), and (2) the pellet of antigen-antibody-pansorbin complex is firmer 
than the pellet of the antigen-antibody-second antibody complex and it is therefore easier 
to completely remove the supernatant after each centrifugation. This allows for greater 
reproducibility in the analytical procedure. 
Validation of the Radioimmunoassay for MRP/PLF 
The identity between the MRP/PLF detected in the plasma of pregnant mice and 
the purified MRP/PLF used as a standard in the radioimmunoassay was checked by com­
paring the slope of the standard curve with the slope of the curve obtained from succes­
sive dilutions of plasma from pregnant mice at mid-gestation. Parallelism of the two 
curves indicates identity (Fig. 8) (Ekins 1969). The identity of the MRP/PLF in plasma 
with the purified MRP/PLF was further indicated by showing the molecular weight and 
immunogenic identity of the two proteins as revealed by Western blotting analysis of 
plasma from a 10 day pregnant mouse. 
Gestational Profile of MRP/PLF in Maternal Plasma 
MRP/PLF concentration in peripheral plasma from CF-1 mice at different days of 
gestation was determined by the previously described radioimmunoassay. Fig. 9 shows the 
gestational profile of MRP/PLF in maternal plasma. Every point on the profile is an 
average of the concentrations from five different mice bled once or twice each (not every 
day). Fig. 10 shows the gestational profiles of MRP/PLF in maternal plasma from two 
different mice. 
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Figure 8. Validation of the MRP/PLF radioimmunoassay by parallelism between the 
standard curve and the plasma dilution curve. (Various concentrations of 
plasma from a 10-day pregnant mouse were analyzed by radioimmunoassay. 
The specific-bound/maximum-bound ratio (B/BQ) for each concentration 
was plotted on the standard curve. An abscissa scale for plasma concentra­
tion is superimposed on the standard curve. The circles represent the 
standard while the square points represent the plasma dilutions) 
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Oty or gestation 
Figure 9. Gestational profiles of the average MRP/PLF concentrations in the mater­
nal circulation of five CF-1 mice. (The concentrations of MRP/PLF in 
plasma samples were measured by the radioimmunoassay. Each point 
represents the average of the concentration in five mice [different mice 
bled once or twice each]. The vertical lines represent the standard 
deviations) 
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Figure 10. Gestational profiles of MRP/PLF concentrations in the maternal circulation 
of individual CF-1 mice. (The concentrations of MRP/PLF were measured 
by the radioimmunoassay. Each profile represents the concentrations of 
MRP/PLF in the plasma of one animal through the course of gestation) 
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Gestational Profile of MRP/PLF in Placental Extract 
Fig. 11 sliows tiie gestational profile of MRP/PLF in placental extract prepared as 
previously described in Methods. The gestational profiles of MRP/PLF in placental 
extracts and in placenta are plotted together in Fig. 12. 
Occurrence of MRP/PLF in Other Tissues 
Extracts from liver, brain, uteri, and mammary gland from CF-1 mice at different 
days of gestation were analyzed for MRP/PLF by the previously described radioimmuno­
assay. None of the extracts contained detectable amounts of MRP/PLF. 
Occurrence of MRP/PLF in Other Species 
Plasma from Sprague-Dawley rats at each day of gestation (day 3-20) and plasma 
from pregnant swine at early, mid, and late gestation (donated by Dr. Lloyd Anderson, 
Animal Science Dept., Iowa State University) were analyzed for MRP/PLF by our radio­
immunoassay. The results revealed the absence of MRP/PLF (detectable by radioimmu­
noassay) from both maternal rat and maternal swine plasma. 
Gestational Profile of Testosterone in Plasma and Placenta of CF-1 Mice 
The levels of plasma testosterone throughout pregnancy in several strains of mice 
have been reported. In all strains examined, a mid-pregnancy increase of testosterone 
concentration in the maternal circulation was observed (Barkley et al. 1979). To establish 
the mid-pregnancy rise in the concentration of testosterone in the maternal blood of CF-1 
mice, the gestational profiles of testosterone in the maternal plasma and in placentae from 
CF-1 mice were examined. 
Fig. 13 shows the testosterone concentration in CF-1 mouse plasma and in placental 
extracts throughout pregnancy. 
Effects of Antiandrogens on the Concentration of EGF In Submaxillary Gland 
and the Concentration of MRP/PLF in Plasma and Placenta During Pregnancy 
The proposed model for the in vivo regulation of the production of MRP/PLF from 
placental cells suggests testosterone as the first effector in the model. To test the effect 
of testosterone on the production of MRP/PLF during CF-1 mouse pregnancy, a group of 
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Figure 11. Gestational profile of MRP/PLF in CF-1 mouse placenta. (The concentra­
tions of MRP/PLF in placental extracts [prepared as described in Methods] 
were measured by the radioimmunoassay. Each point represents the aver­
age concentrations from two placentae, each from a different mouse. The 
concentration of MRP/PLF is reported in pg/jug protein. The vertical lines 
represent the standard deviation) 
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Day Of gestation 
Figure 12. Gestational profile of MRP/PLF in murine placenta superimposed on that 
in maternal circulation. (Values for placenta are represented by squares, 
and values for maternal circulation by circles) 
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Figure 13. Gestational profile of testosterone in the maternal circulation and m the 
placenta of CF-1 mice. (The concentrations of testosterone were measured 
by a radioimmunoassay [described in Methods]. Each point represents the 
concentration in a single animal. The inset represents the standard curve 
for the testosterone radioimmunoassay) 
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pregnant CF-1 mice were treated with either flutamide or cyproterone (antiandrogens) as 
described earlier in Methods. Table 2 shows the effects of the antiandrogens on the 
concentration of EGF in the submaxillary glands obtained from IS pregnant CF-1 mice 
(treatment with antiandrogens started on the sixth day of gestation). Some of the mice 
were found to be not pregnant when killed on the fifteenth day of gestation, although 
they had a vaginal plug on what is designated as day zero of pregnancy. The concentra­
tion of EGF in the submaxillary gland from the inseminated but not pregnant mice is 
compared with the concentration of EGF in the submaxillary glands from pregnant mice 
in Table 3. 
The concentration of MRP/PLF in the placentae collected from the 15-day pregnant 
mice is shown in Table 4. Blood was collected daily from the mice, and the gestational 
profile of MRP/PLF in the maternal plasma is shown in Fig. 14 and in Table S. No 
significant differences are seen in the concentration of MRP/PLF among treated, placebo, 
and non-treated animals. 
MRP/PLF Affinity for the Mannose 6-Phosphate Receptor 
The ability of MRP/PLF in various tissues from pregnant CF-1 mice to bind to the 
mannose 6-phosphate receptor was examined in collaboration with Dr. C. Gabel as 
described earlier in the Methods section of this dissertation. Table 6 shows the amount of 
MRP/PLF applied on the mannose 6-phosphate affinity column from each of the samples 
examined; it also shows the MRP/PLF content of each of the run through and the bound 
fractions from each sample analyzed. Of the MRP/PLF in the amniotic fluid from day 13 
fetus, 4.3% bound to the mannose 6-phosphate receptor. None of the MRP/PLF from 
day 10 maternal blood bound to the mannose 6-phosphate receptor, but more than 50% of 
MRP/PLF from day 13 maternal blood was found to bind to the receptor, and 88% of 
MRP/PLF in placenta from day 13 pregnant mouse was found to bind to the mannose 
6-phosphate receptor. 
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Table 2. Effects of antiandrogens on the concentration of EGF in submaxillary glands 
from 15 day pregnant CF-1 mice 
EGF level 
Treatment® ng/mg protein'* Number of animals 
Cyproterone 5.78 ± 0.88 2 
Flutamide 3.32 ± 1.28 3 
Placebo 7.39 1 
none 5.10 ± 0.47 2 
^Antiandrogen (3.0 mg) suspended in 100 fil solution containing 1% gelatin and 
ISO mM sodium chloride were injected daily into alternate legs of the animals, starting 
from the sixth day of gestation. 
^Mean ± standard deviation. The least significant difference between the means 
was 2.54 ng/mg protein at P = 0.05 (Snedecor and Cochran 1980). 
SI 
Table 3. Comparison of the effect of antiandrogens on the concentrations of EGF in 
submaxillary glands from pregnant and inseminated (but not pregnant) CF-1 
mice 
EGF level (ng/mg protein) 
Treatment^ Pregnant Inseminated^ 
Cyproterone 5.78 ± 0.88 1.55 
Flutamide 3.32 ± 1.28 2.64 
Placebo 7.39 1.64 
none 5.10 ± 0.47 1.41 
^Treatment as described in Table 3. 
^The animals in this group were thought to be pregnant (plug was observed as for 
pregnant mice) but were found to be not pregnant when killed at the fifteenth day after 
plug appearance. There was one animal per treatment. 
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Table 4. Effects of antiandrogen treatment on the concentration of MRP/PLF in 
placentae from IS day pregnant CF-1 mice 
MRP/PLF level 
Treatment® ng/mg protein^ Number of animals 
Cyproterone 69.80 ±4.01 3 
Flutamide 83.55 ± 7.52 3 
Placebo 101.32 ± 24.40 2 
none 88.41 ± 12.40 3 
^Treatment as described in Table 3. 
^Mean ± standard deviation. The least significant difference between the means 
was 30.78 ng/mg protein at f = 0.05. 
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Figure 14. Effect of antiandrogens on the gestational profile of MRP/PLF 
in CF-1 maternal plasma. (Closed circles represent flutamide treated mice, 
open circles represent nontreated mice, closed squares represent cyproterone 
treated animals, while open squares represent placebo treatment) 
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Table S. Effect of antiandrogen treatment on the gestational profile of MRP/PLF in 
CF-1 mouse plasma 
MRP/PLF level (/ig/ml)® 
Day of 
gestation Cyproterone^ Flutamide® Placebo^ none^ not pregnant'^'® 
8 0.32 ± 0.21 0.52 ± 0.45 1.28 0.31 ± 0.11 0.31 
9 3.90 ± 0.99 3.19 ± 0.13 4.33 3.66 ± 0.19 0.36 
10 5.66 ±0.19 4.52 ± 0.22 7.07 5.10 ± 1.00 0.25 
11 5.18 ± 0.12 4.82 ± 0.72 5.66 5.80 ± 0.76 0.12 
12 5.93 ±0.11 5.66 ± 2.91 4.58 5.26 ± 0.96 
13 4.01 ± 0.68 4.74 ± 2.25 2.99 4.82 ± 1.23 
14 2.38 ± 0.59 4.75 ± 2.97 2.53 3.50 ± 0.82 
15 1.82 ± 0.05 3.38 ± 1.65 1.56 2.90 ± 0.94 
^Treatment as described in Table 3; mean ± standard deviation. 
^Two animals were used. 
®Three animals were used. 
single animal was used. 
®The animal was inseminated but not pregnant. 
Table 6. Comparison of the affinity of MRP/PLF from different tissues of pregnant CF-1 mice for the mannose 
6-phosphate receptor 
ng MRP/PLF 
Sample Day of Sample RIA through run- bound total Percent Percent 
source gestation designation No. column through recovery recovery bound 
Amniotic 
fluid 
13 ml 17 AF 13 24 98 66 3 69 71 4.: 
Plasma 5 m81 PA 5 23 0 0 0 0 — 
Plasma 10 m77 PA 10 23 350 359 0 359 102 0 
Plasma 13 ml 17 PA 13 24 219 110 114 224 102 51 
Placental 
extract 
13 ml 17 PL 13 24 28 13 92 105 375 88 
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DISCUSSION 
MRP/PLF was discovered by Nilsen-Hamilton and her co-workers (Nilsen-Hamilton 
et al. 1980), while they were investigating the effects of growth factors on the regulation 
of secreted protein production by a number of clones of 3T3 cells. The same group 
characterized the protein as a family of glycoproteins with approximately 34 kDa 
molecular weight, and they named it Mitogen Regulated Protein (MRP) (Nilsen-Hamilton 
et al. 1980). The same protein was rediscovered by Linzer and Nathans (1983). Linzer 
and Nathans were studying the modulation of mRNA production by growth factor in 
Balb/C 3T3 cells. They identified a putative protein from the cDNA sequence derived 
from a mRNA whose production was found to increase in response to growth factor treat­
ment. The cDNA sequence revealed that the putative protein shares 32% amino acid se­
quence identity with mouse prolactin. The protein will be referred to in this dissertation 
as MRP/PLF. Because 3T3 cells were originally derived from mouse embryos, Linzer and 
Nathans searched for the MRP/PLF mRNA in several adult and fetal mouse tissues, and 
reported the occurrence of the mRNA in the placenta. The amount of mRNA was found 
to be developmentally regulated in Balb/C 3T3 and Swiss Webster mice (Linzer and 
Nathans 1985). They were able to detect mRNA from day 8 of gestation until the end of 
pregnancy and found mRNA peak level at day 10 of gestation. It is important to note 
here that some authors consider the appearance of a plug as day 1 of pregnancy while in 
this dissertation the day of plug appearance is designated as day 0. Jang (1987) reported 
the localization of MRP/PLF protein in CF-1 mouse placenta using immunofluorescence 
and avidin-biotin peroxidase immunocytochemistry. The protein was found to appear on 
day 9 of gestation and was clearly detectable until day 13 of gestation. 
To better understand the regulation of MRP/PLF production by placental cells, I 
developed a radioimmunoassay to determine the concentration of MRP/PLF in various 
tissues from pregnant CF-1 mice and to establish the gestational profile of MRP/PLF in 
the maternal blood of CF-1 mice, pigs, and Sprague-Dawley rats. 
Radioimmunoassays have been widely and successfully used to measure the concen­
tration of polypeptides and other molecules in biological fluids. The assay was first 
developed by Yalow and Berson in 1960. Roslyn Yalow shared the Nobel Prize for 
physiological medicine with Guilleman and Schally in 1977 for her contribution in 
developing the insulin radioimmunoassay. Various protocols have been described for 
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radioimmunoassays. Radioimmunoassays are based on the reaction between a limited 
concentration of antibody with varying concentrations of antigen, and measurements of 
the amount of antigen bound at the various antigen concentrations. Such measurement is 
achieved by using a constant trace amount of radiolabeled antigen. 
Four basic components are essential for setting up a new radioimmunoassay: (a) the 
antigen to be measured, in a purified form for preparing standards containing varying 
amounts of antigen; (b) radiolabeled antigen; (c) a specific antibody for the antigen to be 
measured; and (d) a method for separating the antigen-antibody complex from the free 
antigen. 
In general, performing a radioimmunoassay involves three main steps: 
(1) Incubation. Two types of incubation have been used; the first is to incubate the 
standard or unknown solution with the antibody at a predetermined concentration for 
12-24 hours. Then the radiolabeled antigen is added and the incubation is continued for 
another 24-36 hours. This method of staggering the time of addition of unlabeled and 
radiolabeled antigen provides increased sensitivity for the assay, compared with the second 
type of procedure in which both are added simultaneously (Aubert 1977, Felber 1974). I 
used the procedure with improved sensitivity for setting up the radioimmunoassay for 
MRP/PLF. 
(2) Separation. The separation of free antigen from the antigen-antibody complex 
can be achieved by several methods depending on the characteristics of the antigen to be 
measured. Separation methods may be divided into two main groups (Felber 1974): 
(ii) Methods based on the removal of free antigen from the incubation 
mixture, These methods employ nonspecific adsorbents which have high affinity for the 
free antigen and low affinity for the antigen-antibody complex. These reagents include 
charcoal (Odell 1980), silicates (talc) (Berson and Yalow 1968), and ion-exchange resins 
(Meade and Klitgaard 1962). These methods have been used successfully for the separa­
tion of small polypeptides such as angiotensin and glucagon from their respective antigen-
antibody complexes (Aquilar-Parada et al. 1968). 
(ii) Methods based on the removal of antigen-antibody complex from the 
incubation mixture. These methods employ either specific or nonspecific reagents which 
are capable of precipitating the antibody and antigen-antibody complex from the incuba­
tion mixture. The reagents include anti-i-globulin (second antibody) (Midgley and Hep­
burn 1980), salts (Chard 1980), organic solvents (Desbuquois and Aurbach 1971, Chard 
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1980), and Protein A (Frohman et al. 1979, Ying 1981, Young et al. 1987). The solid 
phase radioimmunoassay belongs to this group of separation methods. The antibody in 
this type of assay is covalently bound to a solid support (immunoadsorbent) (Axen et al. 
1967) or adsorbed to the inside walls of plastic (polystyrene, polypropylene, or 
polyethylene) test tubes (Catt and Tregear 1967). The testosterone radioimmunoassay 
method that I used to estimate the concentration of total testosterone in pregnant mouse 
plasma and in placental extracts provides an example of the solid phase radioimmunoassay. 
Protein A (pansorbin) was used as the precipitating agent for the antigen-antibody 
complex for both the EOF and MRP/PLF radioimmunoassays for the reasons mentioned 
previously in this dissertation. 
(3) Measurements and analysis of results. Measurements of the free or antibody-
bound radiolabeled antigen depends on the type of radioactivity emitted by the isotope 
used to label the antigen. Iodine (^^^I) is the most commonly used radiolabel in radio­
immunoassays. The radioactivity is measured in a gamma spectrometer as counts per 
minute (cpm). 
If the three-dimensional structure and biological activities of the radioiodinated 
protein are preserved (Martin and Murphy 1976), the bound radiolabeled antigen will 
represent a measure of the bound antigen. A calibration curve is set up with antigen 
concentration on the abscissa, and the amount of bound antigen on the ordinate. Such a 
curve is used to determine the concentration of antigen in unknown samples. The results 
can be represented by different types of plots in which the values on the abscissa are 
expressed as the unlabeled antigen concentration or log antigen concentration. The values 
on the ordinate may be represented in various mathematical forms, such as B/T or B/BQ 
where B represents bound cpm, T represents total cpm, and BQ represents the bound cpm 
in the absence of unlabeled antigen (maximum binding). Such dose-response curves are 
sigmoidal and only the central region of the standard curve approaches linearity and can 
be used for comparisons with unknowns. Sigmoidal curves can be partially linearized by 
the use of mathematical transformations (logit, probit, or arc-sine transformations) of the 
response variable (B/BQ) (Rodbard and Frazier 1975). The logit transformation is the 
easiest and it is theoretically justified (Rodbard and Frazier 1975). 
Logit Y = ln[Y/(l-Y)] 
where Y = B/BQ. The logit-log representation requires accurate estimates of BQ and of 
nonspecific binding (N). Nonspecific binding is measured either by replacing the 
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antibody with normal serum or preimmune serum (from the animal in which the antibody 
was raised) or by measuring the bound radioactivity in the presence of "infinite" amounts 
of unlabeled antigen. It is necessary to subtract N from both the numerator and the 
denominator of the B/BQ fraction. 
The dose-response curves for MRP/PLF and EOF shown in this dissertation were 
constructed using the Lotus 1-2-3 program with B/BQ as ordinate and log antigen concen­
tration as abscissa. For the testosterone determination the logit-log representation was 
used. 
Partially purified MRP/PLF contained a single 45 kDa protein contaminant (Fig. 4). 
I purified the protein further by separating it on preparative polyacrylamide gels using the 
SDS-PAGE procedure, followed by electroeluting, extracting, lyophilizing, and resuspend-
ing the protein in 10 mM ammonium bicarbonate (described in Methods). 
Amino acid composition analysis of the purified MRP/PLF provided a reasonable 
estimate of the concentration of MRP/PLF (41 m/mX) which compares well with the esti­
mate obtained from silver stained gels of the MRP/PLF solution (43 ng/ml) (Fig. 5). The 
purified MRP/PLF provided the first essential component for setting up a 
radioimmunoassay. 
MRP/PLF was radioiodinated by the lactoperoxidase-glucose oxidase enzymatic 
method, which was chosen because it is gentler to the protein than the chloramine-T 
method and it avoids the problem of oxidation-mediated protein coupling encountered 
when the chloramine-T method is used for radioiodination (Comens et al. 1982). Radio­
iodinated MRP/PLF provided the second component for setting up the MRP/PLF radio­
immunoassay. Analysis of '^^I-MRP/PLF by SDS-PAGE followed by autoradiography 
revealed the presence of one major band corresponding with '^^I-MRP/PLF and the 
absence of 45 kDa protein (Fig. 5). The availability of anti-MRP/PLF serum and a 
source of immobilized Protein A (pansorbin) provided the other necessary components to 
set up the radioimmunoassay. 
Analysis of murine maternal plasma throughout pregnancy revealed the first 
appearance of MRP/PLF in the CF-1 mouse maternal circulation on day 8 of gestation 
(Fig. 9). The concentration of MRP/PLF in the maternal circulation continued to rise 
until day 10 or 11 of gestation when it reached a peak of approximately 8 /ig/ml. This 
high circulating concentration is not unique to MRP/PLF. mPL-I, which shares 32% 
amino acid sequence identity with MRP/PLF (Colosi et al. 1987) and the same develop-
60 
mental profile in mouse maternal blood, reaches a peak of approximately 7 ng/m\ (Ogren 
and Talamantes 1988) at mid-gestation. MRP/PLF and mPL-I are immunologically dis­
tinct (Lee and Nathans 1988). Lee et al. (1988) have recently reported the gestational 
profile of MRP/PLF in Balb/C mice. They reported an MRP/PLF peak at day 10 of 
pregnancy with levels of about 3.5 fig/ml. The difference between their peak value and 
the peak value reported in this dissertation is probably a reflection of the difference 
between the two strains of mice used. mPL-II is another hormone from the same family 
of polypeptides produced by the placenta; it appears at mid-gestation and continues to rise 
until parturition. The maximum concentration of mPL-II is reached at the end of gesta­
tion and it is reported to be 900 ng/ml (Ogren and Talamantes 1988). MRP/PLF and 
mPL-II are produced by the same cell type, namely the trophoblastic giant cells (Lee et al. 
1988). These cells are located in the placenta close to the maternal circulation (Jang 1987, 
Lee et al. 1988). Data obtained from culturing mouse placental expiants indicate that 
mPL-I is also secreted by the trophoblastic giant cells (Soares et al. 1983, Soares et al. 
1985). 
Analysis of maternal plasma from Sprague-Dawley rats throughout pregnancy and 
also maternal serum from early, mid, and late gestational periods of the pig for MRP/PLF 
by the radioimmunoassay revealed the absence of radioimmunoassayable MRP/PLF from 
both the rat and the porcine maternal blood. The absence of detectable MRP/PLF from 
the maternal blood of these two species does not necessarily mean that the pregnant rat 
and pregnant gilts are devoid of MRP/PLF. If an equivalent protein does exist in these 
two species, then it is not recognized by the rabbit anti-MRP/PLF antibody that we used 
in the radioimmunoassay. 
Rat placenta produces rPL-I and rPL-IL The gestational profiles in the maternal 
circulation for these two proteins are similar to those seen in mice. Porcine placenta, on 
the other hand, does not appear to produce any placental lactogen (Forsyth 1986). Be­
cause of the structural similarity of placental lactogens with PRL and GH, the biological 
activities of placental lactogens have been characterized by the PRL and the GH effects 
of these hormones in various tissues. Several bioassays for PRL are available; they include 
the pigeon crop sac assay (Nicoll 1967), the stimulation of the growth of Nb2 rat lym­
phoma cell cultures (Tanaka et al, 1980), and effects on mouse mammary epithelial cells 
(Thordason et al. 1985). MRP/PLF is not active in stimulating Nb2 rat lymphoma 
proliferation (K. Ebner, personal communication). 
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The specific function(s) of placental lactogens is not yet established in any species. 
More than 85 biological functions have been attributed to prolactin (Nicoll and Bern 
1972). It is possible that some of these functions could be functions of the placental 
lactogens and other placental hormones rather than prolactin. Placental lactogens are 
generally believed to exert their influence via prolactin and growth hormone receptors. 
However, recently a specific receptor for ovine placental lactogen was described 
(Freemark and Handwreger 1986) in the fetal ovine liver. Whereas mPL-I and mPL-II 
seem to bind to the PRL receptor, MRP/PLF does not bind to prolactin receptor (Colosi 
et al. 1987a). 
The developmental profile of MRP/PLF in the mouse maternal blood and in mouse 
placenta coincides with the period of placental proliferation (Jang et al. 1987). The 
amount of MRP/PLF drops rapidly and simultaneously with the termination of placental 
proliferation (Nilsen-Hamilton et al. 1988, submitted). In spite of the correlation between 
the production of MRP/PLF and cellular proliferation in vivo and in cell culture, it is not 
clear whether MRP/PLF exerts a regulatory role on the regulation of cellular proliferation 
or it is itself regulated by regulators present only during cellular proliferation. 
Growth factors such as EOF, FGF, and PDGF stimulate the production of 
MRP/PLF from Swiss and Balb/C 3T3 cells in culture (Nilsen-Hamilton 1980, Linzer and 
Nathans 1983). TGF-a, which is believed to be the fetal form of EGF, binds the EGF 
receptor with equipotency to EGF (Carpenter 1987). The mRNA for TGF-a has been 
localized to the rat decidua from day 8 of gestation through day 14 (Han et al. 1987). 
The developmental profile of MRP/PLF in the mouse maternal blood and in mouse 
placenta coincides with the mid-gestational appearance of TGF-a. Thus it is possible that 
the decidual cells produce TGF-a, which in turn stimulate MRP/PLF production in the 
adjacent basal zone giant cells. EGF receptors have been detected in the placenta (Nexe 
et al. 1980, Adamson et al. 1981) and localized to the trophoblasts (Chegini and Rao 
1985). The giant cells are believed to be derived from trophoblasts; therefore it is 
possible that TGF-a regulates the production of MRP/PLF from the placenta during 
murine embryogenesis. 
Androgens increase the concentration of EGF in submaxillary glands from 
gonadectomized male and female mice (Byyny et al. 1974). Antiandrogens are therefore 
expected to inhibit the production of EGF in the submaxillary gland. Antiandrogens may 
be classified into three groups: first, pure antiandrogens of which flutamide is an example; 
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second, antiandrogens with antigonadotrophic effects of which cyproterone acetate is an 
example; and the third group includes the progestins (Homady et al. 1986). 
The model we propose for the in vivo regulation of MRP/PLF production proposed 
that EOF or its fetal form TGF-a is the inducer of MRP/PLF in placental cells. EOF is 
known to be regulated by testosterone (androgen), and because of the structural and func­
tional similarity between EGF and TGF-a it is likely that the two proteins are regulated 
by the same mechanism, i.e., by androgens. TGF-a is probably the inducer of MRP/PLF 
in the placental cells. TGF-a mRNA has been recently shown by Northern blot analysis 
and by in situ hybridization to be expressed in the maternal decidua of Sprague-Dawley 
rats (Han et al. 1987); the mRNA expression starts after implantation, peaks at day 8 of 
pregnancy, and then slowly declines through day IS when the decidua is being resorbed. 
Wilcox and Derynck (1988) have recently reported that the TGF-a gene is expressed in 
the placenta of CDl mouse at day 9 and 10 of pregnancy. These two recent reports lend 
support to the suggestion that TGF-a is responsible for the induction of MRP/PLF. 
We decided to test the proposed model by determining whether there was any rela­
tion between MRP/PLF concentration and testosterone effects in vivo. I first tested the 
effect of antiandrogens on the concentration of EGF in the submaxillary glands of 
pregnant CF-1 mice to provide the positive control. The results revealed a decrease in the 
EGF concentration in response to flutamide treatment as shown in Table 2. Analysis of 
the concentration of EGF in the submaxillary glands from inseminated but not pregnant 
mice revealed a considerable increase in the concentration of EGF in the submaxillary 
glands from pregnant mice (Table 3). The higher concentration of EGF during pregnancy 
has been shown before (Kurachi and Oka 1985). 
Analysis of MRP/PLF concentration in the placentae and in the maternal plasma 
from flutamide and cyproterone treated animals and from control animals revealed no 
significant difference between the concentration of MRP/PLF in tissues from treated and 
control animals as shown in Tables 4 and S and in Fig. 14. These results are preliminary 
because of the limited number of animals used for each treatment. Definite conclusions 
await further investigations with a larger number of animals. However, if supported by 
more data, the observation that antiandrogens did not affect the concentration of 
MRP/PLF during pregnancy in CF-1 mice does not support the proposed model, that 
testosterone plays a role in in vivo regulation of MRP/PLF production from the placental 
cells of CF-1 mice. 
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None of three animals treated with cyproterone acetate had a healthy pregnancy 
when killed on day 15 of gestation. One animal was not pregnant. The second had 14 
dead fetuses without discernible structure, and with small placentae; the third animal had 
12 fetuses, of which 11 were without any discernible structure, and only one fetus and 
placenta had a normal appearance. It is noteworthy that the MRP/PLF levels in the 
maternal circulation remained normal despite the abnormal fetal development. 
The involvement of estrogens in the in vivo regulation of MRP/PLF needs to be 
investigated because it was shown recently (Diaugustine et al. 1988) that estrogen affects 
the production of EOF precursor protein and its mRNA in mouse uterus. 
The suggested lysosomal degradation of MRP/PLF (crinophagy) (Nilsen-Hamilton et 
al, 1980, Nilsen-Hamilton et al. 1988) and the recent report on the affinity of the 
recombinant MRP/PLF produced by stably transfected Chinese hamster ovary cells to the 
mannose 6-phosphate receptor (Lee and Nathans 1988), together with our interest to 
better understand the structure of MRP/PLF, led us to investigate the affinity of natural 
MRP/PLF (made in vivo during pregnancy) to the mannose 6-phosphate receptor. The 
results (Table 6) show that the affinity of MRP/PLF to mannose 6-phosphate receptor 
depends on the source of MRP/PLF and on the stage of pregnancy. About 4% of 
MRP/PLF in the amniotic fluid from day 13 fetus bound to a mannose 6-phosphate 
receptor affinity column, while 88% of MRP/PLF placental extract from the same mouse 
bound. None of the MRP/PLF in day 10 maternal plasma bound, while more than 50% 
of MRP/PLF in day 13 maternal plasma was found to bind to the mannose 6-phosphate 
receptor. 
The difference in binding between day 13 and day 10 maternal plasma could be part 
of a developmentally regulated mechanism to alter the rate of MRP/PLF clearance from 
the maternal circulation via the mannose 6-phosphate receptor on the liver cells. The 
mannose 6-phosphate receptor itself was recently found to be developmentally regulated 
in pregnant Balb/C mice (Lee and Nathans 1988). The mannose 6-phosphate receptor 
level in the maternal and fetal livers started to rise above the basal level on day 6 of 
pregnancy, reached a peak on day 16, and declined thereafter. The highest receptor 
binding activity was observed in the fetal liver at day 16 of gestation. 
The results of the binding of MRP/PLF to the mannose 6-phosphate receptor in the 
placental extract from day 13 pregnant CF-1 mice is interesting because of the 375% 
recovery of MRP/PLF from the affinity column. The apparent discrepancy could indicate 
64 
the presence of an MRP/PLF binding protein which masks the detection of MRP/PLF in 
the placental extract; MRP/PLF eluted from the affinity column becomes detectable by 
the radioimmunoassay. 
Our collaboration with Dr. Gabel on studying the presence of mannose 6-phosphate 
on MRP/PLF in CF-1 mouse maternal plasma will continue further. Plasma samples from 
day 8 to day 16 of gestation will be analyzed to investigate the developmental regulation 
of the appearance of mannose 6-phosphate on MRP/PLF. 
In summary, I have examined the developmental profile of MRP/PLF throughout 
the pregnancy of CF-1 mice. The results revealed that the first appearance of MRP/PLF 
in the maternal plasma occurs at day 8 of gestation, and the concentration of MRP/PLF 
in the maternal circulation reaches peak (about 8 /tg/ml) at day 10 or day 11 of 
pregnancy. This mid-gestational peak coincides with a peak in the concentration of 
testosterone in the maternal circulation and with the expression of the TGF-a gene in the 
placenta. 
Examination of the effects of antiandrogen treatment on the concentration of 
MRP/PLF in the maternal circulation and in placenta revealed no significant effect of the 
tested antiandrogens on MRPf/PLF concentration in the tissues tested; this indicates that 
testosterone does not play a role in regulating the production of MRP/PLF. 
I also tested for the presence of mannose 6-phosphate on the carbohydrate side 
chain of MRP/PLF in various tissues. My preliminary results indicate that mannose 
6-phosphate appears on MRP/PLF in a developmentally regulated manner. 
The results of these studies laid the foundation for further investigations on these 
topics: 
(a) The developmental regulation of the mannose 6-phosphate appearance on 
MRP/PLF and the significance of the mannose 6-phosphate on regulating the rate of 
MRP/PLF clearance from the maternal circulation. 
(b) The in vivo regulation of MRP/PLF production from the trophoblastic giant cells 
of the placenta, and its relationship with TGF-a. 
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